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ABSTRACT 
Atupele Patience Kapito-Tembo 
Malaria and anemia in HIV-infected pregnant women in Malawi: Associations with 
Cotrimoxazole prophylaxis, Submicroscopic malaria, Iron supplementation and Iron 
deficiency 
(Under the direction of Steven R. Meshnick, MD, PhD) 
 
In HIV-infected pregnant women, we examined the effectiveness of cotrimoxazole 
(CTX) with or without sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment 
of malaria in pregnancy (IPTp) compared to SP-IPTp at reducing malaria and anemia in aim 
1. In aim 2, we investigated the predictors and effects of submicroscopic malaria on anemia. 
In aim 3 we assessed the associations of iron supplementation and iron deficiency with 
malaria.  
Between December 2005 and July 2009, 1,142 HIV-infected pregnant women 
attending Thyolo hospital antenatal clinic in Malawi were recruited in a cross-sectional study. 
Peripheral blood was tested for hemoglobin concentration (Hb) and malaria using 
microscopy and polymerase chain reaction (PCR). Iron biomarkers were measured in 455 
women. Information on socio-demographics, obstetric and medical history, use of malaria 
control interventions was collected using a standardized questionnaire and antenatal 
records.   
For aim 1, women in SP-IPTp plus CTX and CTX groups were less likely to have 
microscopic (Adjusted OR, [95%CI]: 0.09, [0.01-0.66] and 0.43, [0.19-0.97] respectively) or 
PCR-detected malaria infections (AOR, [95%CI]: 0.24, [0.10-0.62] and 0.44, [0.25-0.78] 
respectively) compared to women in the SP-IPTp group. Anemia was lower in the SP-IPTp 
plus CTX and CTX groups than in the SP-IPTp group (Adjusted prevalence ratio (APR), 
[95%CI] 0.67, [0.54-0.83] and 0.72, [0.61-0.83] respectively). For aim 2, submicroscopic 
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malaria was higher in primigravidae compared to multigravidae, during rainy season and in 
women not taking CTX. Mean Hb of women with submicroscopic malaria was lower than in 
women without malaria (Adjusted mean difference=-0.69; 95%CI -1.03,-0.35; p=<0.0001). 
Anemia was higher in women with submicroscopic malaria (APR =1.44; 95%CI 1.18-1.76) 
compared to women without malaria. For aim 3, the prevalence of microscopic and PCR-
detected malaria was similar between women who took iron and those who did not (AOR, 
[95%CI): 2.50, [0.89-7.06] and 1.42, [0.61-3.33] respectively). Women with iron deficiency 
were less likely to have microscopic infection or PCR-detected malaria infection (AOR, 
[95%CI]: 0.22, [0.11-0.47] and 0.21, [0.12-0.39] respectively). 
 Our findings support use of CTX instead of SP for IPTp and submicroscopic malaria 
infection has clinical significance in HIV-infected pregnant women. Iron supplementation 
should not be withheld from HIV-infected pregnant women in Malawi.  
 
v 
 
To my wonderful husband Michael and daughter Nomsa Michelle 
vi 
 
ACKNOWLEDGEMENTS 
I am deeply indebted to Professor Steven Meshnick, my academic advisor during my 
training at UNC-Chapel Hill. I am most grateful for your encouragement, guidance and help 
enabling me to have this once in a lifetime chance to study at UNC-Chapel Hill. I am 
thankful for all your efforts in acquiring funds for my studies and wellbeing. I also wish to 
thank William C. Miller, Anna-Maria Siega-Riz and Audrey E. Pettifor, my dissertation 
committee members, for their time, insightful comments and support while working on this 
document.   
To Dr Victor Mwapasa, the principal investigator of the “Iron supplementation in HIV-
infected pregnant women study-(IHIP) “, I do not know how to express my gratitude to you.  
Your generosity in letting me use the IHIP project data for my dissertation was 
overwhelming. I also thank you for your encouraging and insightful comments as well as 
your support throughout my dissertation work. I will continue to learn from you and William 
C. Miller on good academic writing.  
I thank the Steven Meshnick laboratory team at UNC-Chapel Hill for all the 
assistance and support they rendered to me while I was working on the study samples. 
Special thanks to Steve “T-bone” Taylor for teaching me how to conduct real-time 
polymerase chain reaction tests for malaria. Thanks to Stephanie Carrier and Paul Trottman 
for all your assistance whenever I needed help in the lab.  
The IHIP project would not have been possible and a success without the dedicated 
and hard working research staff and participation of the HIV-infected pregnant women in 
Malawi. Special thanks to Mrs Linness Mphuka and all the IHIP research nurses for 
vii 
 
collected data for the project. I wish to acknowledge Mr Visopo Harawa, Mr James 
Mpalapandu and Mr Yohane Makuta for their work on microscopy. We are grateful to the 
Médecins Sans Frontières (MSF) – Luxembourg staff at Thyolo district hospital, Dr Beatrice 
Mwagomba and the entire Thyolo district hospital management team for their great support 
throughout the lifespan of the IHIP project. 
I thank the American people who have funded my studies at UNC-Chapel Hill 
through the NIH-Fogarty Infectious Disease Epidemiology Training grant (NIH/FIC 5 D43 
TW006568) under Professor Steven Meshnick. I also wish to acknowledge the NIH for 
funding the IHIP project (grant number 5R01TW007305). Thanks to Kirsten Leysieffer for all 
the help you rendered to me during my stay in the US.  
I am very grateful to my mother for striving to have her children educated despite 
great challenges and for all her prayers. Finally, I extend my heartfelt gratitude to my dear 
husband, Michael. I thank you for being a pillar of support and for your encouragement 
throughout my training at UNC-Chapel hill. You always have confidence in me which I 
usually lack. May God bless you abundantly for all the sacrifices you have made! And to our 
daughter, Nomsa Michelle, thank you for helping me put my priorities in order!     
 
 
 
 
 
viii 
 
TABLE OF CONTENTS 
LIST OF TABLES ………………………………………………………………………………….xii 
LIST OF FIGURES ............................................................................................................................ xiv 
LIST OF ABBREVIATIONS ............................................................................................................... xv 
CHAPTER 1: OVERVIEW, BACKGROUND AND SIGNIFICANCE ............................................ 1 
1.1 Overview ............................................................................................................................... 1 
1.2 The malaria parasite ............................................................................................................ 1 
1.3 Clinical presentation of malaria ......................................................................................... 2 
1.4 Epidemiology of malaria ..................................................................................................... 3 
1.5 Malaria in pregnancy ........................................................................................................... 4 
1.5.1 P. falciparum malaria in pregnancy ........................................................................... 4 
1.5.2 P. vivax, P.ovale and P. malariae in pregnancy ...................................................... 5 
1.5.3 Pathophysiology of malaria in pregnancy ................................................................ 5 
1.5.4 Effect of HIV on malaria in pregnancy ...................................................................... 7 
1.5.5 Effect of malaria on HIV in pregnancy ...................................................................... 8 
1.5.6 Submicroscopic malaria in pregnancy ...................................................................... 9 
1.5.7 Prevention and control of malaria during pregnancy ............................................ 10 
1.6 Iron and malaria infection ................................................................................................. 11 
1.7 Laboratory evaluation of malaria infection ..................................................................... 13 
1.8 Iron deficiency and anemia .............................................................................................. 14 
1.8.1 Epidemiology of iron deficiency and anemia ......................................................... 14 
1.8.2 Effects of Iron deficiency and anemia on pregnancy ........................................... 15 
1.8.3 Iron in the body systems ........................................................................................... 15
ix 
 
1.8.4 The function of iron in the immune system ............................................................ 16 
1.8.5 The function of iron in infections .............................................................................. 19 
1.8.6 Effect of HIV on anemia and iron metabolism ....................................................... 19 
1.8.7 Iron supplementation in pregnancy ......................................................................... 21 
1.8.8 Diagnosis of anemia and iron deficiency ................................................................ 23 
1.9 Summary of background................................................................................................... 23 
CHAPTER 2: SPECIFIC AIMS ........................................................................................................ 25 
2.1 Specific aim 1 ..................................................................................................................... 25 
2.2 Specific aim 2 ..................................................................................................................... 26 
2.3 Specific aim 3 ..................................................................................................................... 27 
CHAPTER 3: RESEARCH DESIGN AND METHODS ................................................................ 29 
3.0 Overview of methods......................................................................................................... 29 
3.1 Study design ....................................................................................................................... 29 
3.1.1 Study site .................................................................................................................... 30 
3.1.2 Study population ........................................................................................................ 30 
3.1.3 Data collection ............................................................................................................ 31 
3.1.4 Data cleaning and quality control ............................................................................ 34 
3.2 Methods for Aim 1 .............................................................................................................. 34 
3.2.1 Study site, population and data collection.............................................................. 34 
3.2.2 Classification of exposure ......................................................................................... 34 
3.2.3 Classification of outcomes ........................................................................................ 34 
3.2.4 Statistical analysis ..................................................................................................... 35 
3.3 Methods for Aim 2 .............................................................................................................. 42 
3.3.1 Study site, population and data collection.............................................................. 42 
3.3.2 Classification of exposure ......................................................................................... 42 
x 
 
3.3.3 Classification of outcomes ........................................................................................ 42 
3.3.4 Statistical analysis ..................................................................................................... 42 
3.4 Methods for Aim  3............................................................................................................. 45 
3.4.1 Study site, population and data collection.............................................................. 45 
3.4.2 Classification of main exposures ............................................................................. 45 
3.4.3 Classification of outcomes ........................................................................................ 45 
3.4.4 Statistical analysis ..................................................................................................... 45 
CHAPTER 4: MARKED REDUCTION IN PREVALENCE OF MALARIA AND ANEMIA IN 
HIV-INFECTED PREGNANT WOMEN TAKING COTRIMOXAZOLE WITH OR WITHOUT 
SP-IPT IN MALAWI ........................................................................................................................... 49 
Abstract ........................................................................................................................................... 49 
Introduction ..................................................................................................................................... 50 
Methods ........................................................................................................................................... 51 
Results ............................................................................................................................................. 54 
Discussion ....................................................................................................................................... 56 
CHAPTER 5: ASSOCIATION BETWEEN SUBMICROSCOPIC MALARIA INFECTION AND 
MATERNAL ANEMIA IN HIV-INFECTED PREGNANT WOMEN IN MALAWI ........................ 64 
Abstract ........................................................................................................................................... 64 
Introduction ..................................................................................................................................... 65 
Methods ........................................................................................................................................... 66 
Results ............................................................................................................................................. 68 
Discussion ....................................................................................................................................... 70 
CHAPTER 6: ASSOCIATION OF IRON SUPPLEMENTATION AND IRON DEFICIENCY 
WITH MALARIA INFECTION IN HIV-INFECTED PREGNANT WOMEN IN MALAWI .......... 78 
Abstract ........................................................................................................................................... 78 
Introduction ..................................................................................................................................... 79 
Methods ........................................................................................................................................... 80 
xi 
 
Discussion ....................................................................................................................................... 85 
CHAPTER 7: CONCLUSION ........................................................................................................... 93 
7.1 Summary of findings .......................................................................................................... 93 
7.2 Strengths of the study ....................................................................................................... 93 
7.3 Limitations of the study ..................................................................................................... 94 
7.4 Public health implications ................................................................................................. 95 
References ......................................................................................................................................... 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
 
 
 
LIST OF TABLES 
 
Table 1.1: Studies on iron supplementation and malaria infection in pregnancy ..................13 
 
Table 4.1: Characteristics of HIV-infected pregnant women according to SP-IPTp and CTX 
intake during pregnancy attending Thyolo district hospital antenatal clinic (2005-2009)
 .....................................................................................................................................60 
 
Table 4.2: Factors associated with malaria infection among HIV-infected pregnant women 
from Thyolo district hospital antenatal clinic in Malawi (2005-2009) ..............................61 
 
Table 4.3: Maternal anemia (Hb<11g/dl) and hemoglobin concentration (Hb)  by anti-malaria 
drug group in HIV-infected pregnant women at Thyolo district hospital, Malawi (2005-
2009) ............................................................................................................................62 
 
Table 5.1: Factors associated with submicroscopic malaria infection in HIV-infected 
pregnant women attending Thyolo district hospital antenatal clinic in Malawi (2005-
2009) ............................................................................................................................74 
 
Table 5.2: Characterization of HIV-infected pregnant women by malaria infection attending 
Thyolo district hospital antenatal clinic, Malawi (2005-2009) ........................................75 
 
Table 5.3: Factors associated with maternal anemia in HIV-infected pregnant women 
attending Thyolo district hospital antenatal clinic in Malawi (2005-2009) ............ ERROR! 
BOOKMARK NOT DEFINED.76 
 
Table 5.4: Hemoglobin concentration (Hb) by malaria infection in HIV-infected pregnant 
women at Thyolo district hospital, Malawi (2005-2009) ................................................77 
 
Table 6.1: Characteristics of HIV-infected pregnant women by iron supplementation 
attending Thyolo district hospital antenatal clinic, Malawi (2005-2009) .........................89 
xiii 
 
 
Table 6.2: Iron supplementation and iron status biomarkers in HIV-infected pregnant women 
at Thyolo district hospital, Malawi (2005-2009) .............................................................90 
 
Table 6.3: Factors associated with iron deficiency in 455 HIV-infected pregnant women 
attending Thyolo district hospital antenatal clinic in Malawi (2005-2009) ......................91 
 
Table 6.4: Association of iron supplementation and iron deficiency with malaria infection in 
HIV-infected pregnant women attending Thyolo district hospital antenatal clinic, Malawi 
(2005-2009) .................................................................................................................92 
xiv 
 
LIST OF FIGURES 
Figure1.1:  Life cycle of the malaria parasite ........................................................................ 3 
 
Figure 1.2: Proposed mechanisms how iron supplementation increases the risk of malaria 
infection........................................................................................................................11 
 
Figure 3.1: Enrollment protocol for IHIP study .....................................................................31 
 
Figure 3.2: Directed acyclic graph for the association between anti-malaria drug exposure 
and malaria infection ....................................................................................................40 
 
Figure 3.3: Directed acyclic graph for the association between anti-malaria drug exposure 
and maternal anemia....................................................................................................41 
 
Figure 3.4: Directed acyclic graph for the association between submicroscopic malaria and 
maternal anemia ..........................................................................................................44 
 
Figure 3.5: Directed acyclic graph for the association between iron supplementation and 
malaria infection ...........................................................................................................47 
 
Figure 3.6: Directed acyclic graph for the association between iron deficiency and malaria 
infection........................................................................................................................48 
 
Figure 4.1: Prevalence of malaria with 95% ci by anti-malarial drug intake in HIV-infected 
pregnant women at Thyolo district hospital, Malawi (2005-2009) .................................63 
 
 
 
xv 
 
LIST OF ABBREVIATIONS 
 
ACD  Anemia of chronic disease 
ART  Antiretroviral therapy 
ARVs  Antiretroviral drugs 
CRP  C-Reactive protein 
CTX  Cotrimoxazole 
DAG  Directed acyclic graph 
Hb  Hemoglobin concentration 
HIV  Human Immununodeficiency Virus  
ID  Iron deficiency 
IEs  Infected erythrocytes 
IHIP  Iron supplementation in HIV-Infected pregnant women  
IPTp  Intermittent Preventive Treatment of Malaria in pregnancy 
ITNs   Insecticide-treated nets 
LBW  Low birth weight 
MUAC  Mid-upper arm circumference 
PCR  Polymerase Chain Reaction 
rbcs  red blood cells 
SES  Socio-economic status 
SSA  Sub-Saharan Africa 
SP  Sulfadoxine-Pyrimethamine 
sTfR  serum transferring receptors 
WHO  World Health Organization 
 
  
CHAPTER 1: OVERVIEW, BACKGROUND AND SIGNIFICANCE 
1.1 Overview  
The first aim of this work was to assess the effectiveness of cotrimoxazole (CTX) 
with or without sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of 
malaria during pregnancy (IPTp) compared to SP-IPTp only at reducing malaria infection 
and anemia in HIV-infected pregnant women. The second aim was to identify the predictors 
of and assess whether submicroscopic malaria infection increases anemia in HIV-infected 
pregnant women. The third aim was to investigate whether routine iron supplementation 
increases malaria infection in HIV-infected pregnant women. We also assessed whether iron 
deficiency was associated with reduced malaria infection in this population. 
This chapter briefly reviews the epidemiology of malaria, iron deficiency and anemia 
in pregnancy. It also reviews the effects of HIV on malaria, anemia and iron metabolism with 
focus on pregnant women. 
1.2 The malaria parasite 
Malaria is caused by protozoa of the Plasmodium genus and is transmitted between 
persons through a female Anopheles mosquito bite. P. falciparum, P. vivax, P. malariae, P. 
ovale and P. knowlesi cause disease in humans. P. falciparum and P. vivax cause the 
majority of infections and the most severe malaria disease.  
The malaria parasite passes through a sequence of three types of reproduction: a) a 
single cycle of sexual reproduction, the "sporogonic cycle", in the Anopheles host; b) a 
single cycle of asexual reproduction, the "exo-erythrocytic cycle", in a liver cell of the human 
host; and c) an indefinite number of runs of asexual reproduction, the "erythrocytic cycle", in 
the red blood cells (rbcs) of the human host (Figure 1.1) [1].  
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During the erythrocytic cycle some parasites differentiate into male and female 
gametocytes which, if taken in with the blood meal of an Anopheles mosquito, initiate the 
sporogonic cycle. The sporogonic cycle takes between 9 and 30 days or longer depending 
on the species and temperature. The gametocytes mature and fertilize in the stomach of the 
mosquito to produce a motile egg which divides into motile sporozoites. The sporozoites 
invade the salivary glands and infect a human host during a bite. Sporozoites reach liver 
cells within 30 minutes where each successful sporozoite develops into a mature liver 
schizont. Each schizont burst and liberate into the blood at least 20,000 merozoites which 
invade red blood cells. The time needed to multiply in the liver varies with the parasite 
species: 6 to 12 days for P. falciparum, 14 to 30 days for P. malariae, 8 to 20 days for P. 
vivax, and 12 to 20 days for P. ovale. However, P. vivax and P. ovale parasites may remain 
dormant in the liver for months or years as a hypnozoite before infecting the red blood cells 
causing malaria relapses after the initial malaria episode. 
Merozoites penetrate red blood cells and initiate the erythrocytic cycle by maturing 
into blood schizonts. These burst and release 8 to 24 new merozoites (depending on the 
parasite species) that rapidly invade more red blood cells. This takes 48 hours for the so-
called tertian malarias (benign in the case of P. vivax and P. ovale; malignant in the case of 
P. falciparum) and 72 hours for the quartan malaria (P. malariae).  P. vivax and P. ovale 
selectively invade young erythrocytes and P. malariae selects the old, while P. falciparum 
indiscriminately invades any.  
1.3 Clinical presentation of malaria 
Clinical features result from parasitization and destruction of rbcs and vary 
depending on the degree of acquired immunity before pregnancy [2]. In low, unstable or 
seasonal malaria transmission areas, pregnant women have little or no acquired immunity 
against malaria. Maternal infections in these areas usually present with symptoms of acute 
malaria such as fever, malaise, headaches, muscular pains, sweats, chills, nausea, vomiting 
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and diarrhea [3]. Pregnant women develop more severe malaria disease which increases 
the risk of maternal and fetal deaths [4]. Symptoms of severe disease include; confusion, 
convulsions, loss of consciousness (“cerebral malaria”), anemia, respiratory distress, shock, 
spontaneous bleeding, macroscopic hemoglobinuria, jaundice and hyperpyrexia. In rare 
cases, renal failure and pulmonary edema can occur. In high and stable malaria 
transmission areas, pregnant women are semi-immune. In these areas, most infected 
pregnant women are asymptomatic [5]. They may only present with severe anemia due to 
frequent infections [6] or may only complain of non-specific symptoms of malaria without 
fever [7].  
Figure1.1: Life cycle of the malaria parasite 
 
1.4 Epidemiology of malaria 
Each year, 300-500 million new clinical malaria cases occur leading to 1.5-2.7 million 
deaths worldwide [8].  90% of these cases occur in the sub-Saharan Africa (SSA) where P. 
falciparum causes 93% of the infections [9]. 1 million deaths occur in Africa among children 
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under the age of five years.  In high and stable malaria transmission areas, adults acquire 
malaria immunity following repeated malaria infections during childhood. Hence, infected 
adults in these areas are usually asymptomatic and less likely to develop severe malaria 
[10]. Pregnant women are more susceptible to malaria because their acquired immunity is 
reduced during pregnancy [11]. 
1.5  Malaria in pregnancy 
1.5.1 P. falciparum malaria in pregnancy 
At least 25 million pregnant women in malaria stable transmission areas of SSA are 
exposed to P. falciparum malaria each year [12]. P. falciparum malaria during pregnancy 
increases the risks of abortion, preterm delivery, maternal anemia and low birth 
weight (LBW) [13-15]. LBW babies have increased risk of neonatal and infant morbidity and 
mortality. P. falciparum malaria infection is associated with severe adverse effects in 
pregnancy because unlike other plasmodium species, P. falciparum parasites sequester in 
the maternal vascular space of the placenta thereby evading the immune system [16, 
17].The risk of malaria is highest during the second trimester compared to the first or third 
trimester [15, 18]. However, other studies have reported increased risk in the first trimester 
[19]. Women in their first or second pregnancy have a higher risk of malaria and its 
complications and decreases in subsequent pregnancies [20]. This effect of gravidity on 
malaria risk is absent during malaria epidemics and is less marked in low transmission areas 
[4, 21, 22]. Young primigravid and multigravid women living in high and stable malaria 
transmission areas, particularly adolescents, have a higher risk of malaria and its adverse 
effects compared to older primigravidae and multigravidae respectively [23, 24, 25]. 
Although P. falciparum has been shown to cause significant adverse effects on the mother 
and the fetus, others suggest this may be due to the fact that P. falciparum has been 
extensively studied than the other species [5, 26].    
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1.5.2 P. vivax, P.ovale and P. malariae in pregnancy 
Data on P. vivax infections are mostly from South-East Asia and South America. 
Robust data on the prevalence and effects of P. ovale and P. malariae in any population, let 
alone during pregnancy, are currently unavailable [2, 5].  
The risk of P. vivax infection is higher in pregnant women, however, the risk is less 
pronounced compared to P. falciparum [2]. In Brazil, the ratio of P. falciparum to P. vivax 
was 1:5·6 in non-pregnant women but it was only half that (1:2·3) in pregnant women [27]. 
Compared to non-pregnant women, pregnant women with P. vivax are more likely to present 
with P. vivax relapses [28]. Contrary to previous thought that P. vivax infection has no 
adverse effects, new evidence suggests that P. vivax infections are associated with reduced 
maternal hemoglobin and birth weight [28]. However, the effects seem smaller compared to 
P. falciparum.  
The limited information on P. ovale and P. malariae seem to suggest that based on 
microscopy, their prevalence is low [2, 5]. However, recent polymerase chain reaction (PCR) 
studies suggest this is a gross underestimate since most P. ovale and P. malariae infections 
are not evident by microscopy [29]. In SSA, these often present as co-infections with P. 
falciparum. A Cameroonian study found a higher prevalence of mixed infections among 
pregnant women than previously recognized [24]. These mixed infections decreased with 
increasing age and gravidity but were not associated with maternal anemia. 
1.5.3 Pathophysiology of malaria in pregnancy 
Sequestration of parasites 
P. falciparum infection during pregnancy is characterized by placental malaria. 
Placental malaria refers to the sequestration of plasmodium-infected erythrocytes (IEs) in 
the placental intervillous spaces [30]. P. falciparum IEs undergo antigenic variation, by 
switching expression of variant surface antigens (VSAs), which facilitates evasion of the 
malaria immunity during pregnancy [31]. Sequestration of IEs is mediated by adhesive 
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interactions between the parasite antigens on the surface of erythrocytes, P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) and a glycosaminoglycan receptor expressed by 
syncytiotrophoblasts lining the placental intervillous spaces called chondroitin sulphate A 
(CSA) [32, 33]. Hyaluronic acid (HA) and non-immune IgG have also been proposed as 
receptors for P. falciparum adhesion in the placenta, but evidence for their roles is 
inconclusive [32, 34]. Furthermore, placental parasites rarely bind to CD36 receptors and 
intercellular adhension molecule (ICAM-1) which mediate adhesion in the brain [35, 36].  
CSA binding IEs, unlike other IEs bind IgM, and has been suggested to promote 
sequestration as well [37]. Antibodies against placental IEs reduce the likelihood of malaria 
infection and are associated with improved maternal and fetal pregnancy outcomes [38, 39]. 
These antibodies are increasingly acquired over successive pregnancies.  
As a result of placental parasite sequestration, parasites can be detected in the 
placenta but not in the peripheral blood [40]. This creates a great challenge in the 
parasitological diagnosis of malaria during the antenatal period of pregnancy when 
placenta is not accessible.  
Cellular immune response    
Infection of the placenta by P. falciparum stimulates an inflammatory response. 
Inflammatory cells such as lymphocytes, macrophages and monocytes infiltrate the 
placental intervillous space [42]. It is suggested that chemokines produced by monocytes 
and syncytiotrophoblast probably attract monocytes to the placenta [43] including 
neutrophils and T cells [44]. Macrophages limit the infection by engulfing the parasites and 
producing Th1 cytokines. Increased production of inflammatory cells cytokines such as 
tumor necrosis factor (TNF), interleukin-2 (IL-2), and interferon-gamma (INF-γ) has an effect 
on the course and outcome of placental malaria [reviewed in [45]]. Levels of TNF have been 
associated with LBW and anemia, while IFN- γ production in vitro by placental cells has 
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been associated with decreased placental malaria.  Peripheral blood T cell responses may 
be decreased in malaria [46] due to trafficking of memory T cells out of the circulation. 
However, the relationship between T-cell responses and pregnancy outcomes has not been 
studied. 
Humoral immune response 
Antibodies against parasite antigens mediate protection through various mechanisms 
which includes; blocking invasion of parasites into host cells, phagocytosis and antibody-
dependent inhibition of cellular growth [reviewed in [47] ]. Antibody levels are lower in 
pregnant women compared to non-pregnant women, and in primigravidae compared to 
multigravidae. Levels of antibodies to certain P. falciparum antigens such as merozoite 
surface protein (MSP)-1 19kDa and Pf155/ring-infected erythrocyte surface antigen (RESA) 
are associated with placental malaria infection [47]. Primigravid women lack, or have 
delayed production of antibodies that can block the binding of P. falciparum parasites to 
CSA, but multigravid women possess these antibodies or acquire them earlier in pregnancy. 
Studies have found that women with high levels of anti-CSA-binding antibodies have 
reduced placental parasitemia, reduced maternal anemia and increased infant birth weight 
[47]. 
1.5.4 Effect of HIV on malaria in pregnancy 
The risk, severity and effects of malaria infection are higher in HIV-infected 
pregnant women compared to HIV-negative pregnant women [reviewed in [48]]. In 
SSA, HIV infection among pregnant women ranges from 10% to 40% and accounts for 10% 
to 27% of malaria in pregnancy [6, 48, 49]. Compared to HIV-negative pregnant women, 
HIV-infected pregnant women have higher risk of placental and peripheral malaria, high 
density parasitemia and febrile malaria illness [22, 48-50]. HIV increases the degree to 
which malaria is associated with severe anaemia and low birthweight [48]. In pregnant 
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women, HIV infection eliminates the effect of gravidity on malaria such that the risk of 
malaria is high not only in primigravid women but in women of all gravidities [2, 22].  
HIV-infected pregnant women have reduced and impaired humoral immune 
response to malaria [51, 52]. Women with a low CD4 T-cell count and advanced HIV 
disease show the greatest impairment [51]. Evidence suggests that HIV reduces antibody 
response to some P. falciparum antigens but does not cause a generalized suppression or 
reduction of humoral immune responses to malaria antigens in pregnant women [reviewed 
in [47]]. This is because while antibody responses to blood-stage antigen AMA-1 have been 
found to reduced in HIV-infected women {{1852 Mount,A.M. 2004}}, no consistent HIV-
associated differences have been observed in other antigenic determinants such as 
MSP119kD, MSP-2, MSP-3 and RAP1. The reason for the selective compromise of antibody 
responses to only a subset of parasite antigens is still unclear.  
HIV infection reduces the efficacy of some anti-malarial drugs [53-56].  
Compared to HIV-infected women who received 2 doses of SP-IPTp, HIV-infected women 
who received monthly doses of SP-IPTp were less likely to have placental malaria (RR 0.36; 
95% CI: 0.17-0.79) [53, 56]. However, other studies have reported no difference in the risk 
of malaria between the two regimens [55].  
1.5.5 Effect of malaria on HIV in pregnancy 
Malaria facilitates HIV-1 progression by activating T cells or by inducing the release 
of immune factors such as TNF-α that can activate HIV-1 replication [reviewed in [47]]. In 
Malawi, placental malaria was associated with a twofold increase in placental HIV-1 RNA 
concentration [57]. There was also a 1.7-fold increase in peripheral HIV-1RNA 
concentration, and positive correlations between both peripheral and placental HIV-1 RNA 
concentrations and placental parasite density [57].  Acute P. falciparum infection increases 
HIV viral load with the largest increases in those with high-density parasitemia and/or fever, 
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but viral load declines following malaria treatment [58]. However, some studies have found 
no association between placental malaria and peripheral viral load [59, 60]. 
1.5.6 Submicroscopic malaria in pregnancy 
Prevalence and risk factors 
The reported prevalence of submicroscopic malaria in pregnant women in malaria-
endemic areas ranges from 18% to 55% [24, 41, 61-64]. Little is known about factors that 
influence the occurrence of submicroscopic malaria [65]. However, it is suggested that the 
acquired malaria immunity possibly reduces the density of malaria parasites to low grade 
levels not detectable by microscopy [66]. While some studies have found submicroscopic 
malaria infection to increase with increasing age and gravidity [41, 61], others have found no 
association [24, 62]. Use of anti-malarial drugs [41] has been shown to be associated with 
higher rates of submicroscopic malaria.  
Malaria parasitemia may be reduced to submicroscopic levels in HIV-infected 
pregnant women. They use more anti-malarial drugs than HIV-negative pregnant women 
[48]. First, treatment of all fevers as malaria in HIV-infected patients living in malaria-
endemic areas causes increased and unnecessary intake of anti-malarial drugs. Only 15% 
of fever reporters had parasitemia in Malawian adults [67]. Second, some drugs for the 
treatment of HIV and HIV-related diseases such as antiretroviral drugs (ARVs) and 
cotrimoxazole (CTX) have some anti-malarial effects [68-71]. Third, World Health 
Organization (WHO) recommends more drug doses in HIV-infected pregnant women for 
intermittent preventive treatment of malaria (IPTp).  
Effects of submicroscopic malaria 
The clinical importance of submicroscopic malaria in pregnancy is unclear. While 
some studies have found an association between submicroscopic malaria infection and 
maternal anemia or LBW [41, 72, 73], others have not [24, 61, 62, 64].  No study has 
reported the effect of submicroscopic malaria in HIV-infected pregnant women. 
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However, it may be of clinical significance in this population since their immunity is 
impaired. 
1.5.7 Prevention and control of malaria during pregnancy  
WHO recommends use of insecticide-treated nets (ITNs) or long lasting insecticidal 
nets (LLINs), effective case management of malaria illness and intermittent treatment of 
malaria (IPT) to control malaria during pregnancy [74].  
ITN or LLIN use is recommended throughout pregnancy to provide a physical barrier 
and reduce mosquito bites. The imbedded insecticides kill, repel or prevent mosquitoes from 
feeding.  
IPTp, the periodic administration of anti-malarial drugs during pregnancy irrespective 
of clinical illness or presence of malaria parasites, has been shown to reduce malaria 
infection by 38% [75]. This clears malaria parasites from the placenta and peripheral blood 
during phase of increased fetal growth and allows hematological recovery during pregnancy. 
In stable malaria transmission areas, pregnant women ought to receive at least 2 doses of 
SP-IPTp. In areas where the prevalence of HIV is more than 10%, at least 3 doses of SP-
IPTp are recommended except if the woman is on daily CTX prophylaxis for the treatment of 
opportunistic infection [3, 76]. CTX has been shown to have some anti-malarial effects in 
children and HIV-infected adults [70, 77-79]. It has been suggested that the risk of adverse 
drug reactions may be increased if SP-IPTp and CTX prophylaxis for opportunistic infection 
are taken together since both contain sulphur [80].  Both these drugs are anti-folates as well 
and have potential to increase the risk of fetal neural tube defects. However, there are no 
data on the efficacy, effectiveness and safety of CTX prophylaxis for preventing 
malaria in HIV-infected pregnant women.  
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Iron 
supplementation 
Increased labile iron in 
cytoplasm of red blood 
cells 
Increased young red 
blood cells formation 
Increased malaria 
parasites 
Figure 1.2: Proposed mechanisms how iron 
supplementation increases the risk of malaria 
infection 
1.6 Iron and malaria infection 
Iron and the malaria parasite 
Iron is required by malaria parasites for synthesis of iron containing proteins 
particularly during the schizogony phase to meet demand for ribonucleotide reductase, an 
iron-dependent enzyme involved in the production of nucleotides for parasite DNA 
replication [81]. The parasite lives in an exceedingly iron rich environment inside the rbcs. 
Studies in mice found that high iron levels 
were associated with increased malaria 
parasites [82]. The specific sources of iron 
or the mechanisms through which iron 
affects parasite invasion or growth are not 
fully understood (reviewed in [83, 84]). 
Serum iron, free erythrocytic iron and 
hemoglobin are the possible sources [84]. 
Four theories have been proposed to 
explain how iron status may influence 
susceptibility to malaria [reviewed in [85]]. First, it is thought that during the red blood cell 
stage of malaria infection, the parasite is dependent on the small pool of labile iron in the 
cell cytoplasm [83, 86]. The concentration of labile iron in the cytoplasm is thought to be 
sensitive to nutritional influences including iron supplementation (Figure 1.1) [83, 87]. This is 
confirmed by a study in mice which showed that inhibition of malaria parasite growth was 
achieved in red blood cells independent of the of iron status level [88]. Second, it is 
suggested that iron supplementation enhances malaria susceptibility by stimulating 
formation of young red blood cells. This increases the risk of infection with P.vivax and P. 
ovale species that have preference for young red blood cells [89]. Third, in iron deficiency 
state, zinc protoporphyrin is produced and is thought to inhibit detoxification of heme, and 
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this generates a toxic environment which acts as an antimalarial drug [90]. Fourth, it is 
thought that iron may directly influence the host’s immunity.  
Observational and Clinical studies in pregnant women  
Few published studies have reported on iron supplementation and malaria in 
pregnant women [91-94] (Table 1.1). Evidence suggests that iron deficiency (ID) reduces 
the risk of malaria in pregnant women living in malaria-endemic areas [95, 96]. This implies 
that iron supplementation in pregnant women living in malaria-endemic areas could 
increase the incidence and severity of malaria infection. 
Results from published studies that have reported on the effect of iron 
supplementation on malaria in pregnant women are conflicting [91-94] (Table 1.1). Possible 
explanations for the observed differences include differences in the study participants, 
routes of iron administration, level of malaria transmission in the study area and study 
methods and design. In Thailand and Papua New Guinea studies, differences between the 
treatment groups and the comparison groups could have confounded the results. Iron was 
provided only to women who had anemia and the comparison group was composed of 
women without anemia [92, 93]. Women in the treatment group in Papua New Guinea 
received intravenous iron while the treatment group in the Gambian study received oral iron. 
Also, one of the problems with the previous studies was that parasites were detected 
using microscopy. During pregnancy, parasites may sequester in the placenta and 
microscopy of peripheral blood could underestimate malaria infection [64, 97]. 
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Table 1.1: Studies on iron supplementation and malaria infection in pregnancy 
Author, Year 
Location and 
malaria 
transmission 
Study design (study 
population) 
Iron 
supplementation 
route 
Treatment and 
comparison 
Outcome Estimate 
(95% CI) 
Comments 
( malaria 
prevalence 
in study ) 
Oppenheimer 1986 Papua New 
Guinea 
 
High malaria 
transmission 
 
Prospective cohort 
(Women of all 
gravidity) 
Intravenous iron 
infusion provided to 
women with Hb 
8g/dl only. 
Ferrous sulphate 
tablets was 
routinely provided 
to all mothers at 
the antenatal clinic 
 
IV iron (167 ) vs. 
?Routine iron 
(377) 
 
Primipara Odds ratio 
5.46 (2.20, 13.53) 
Multipara Odds ratio 
1.12 (0.73-1.70) 
 
Primipara 
women had 
significantly 
more 
intravenous 
infusions 
antenatally 
(9%) 
Menendez, 1994 Rural Gambia 
Seasonal and 
high malaria 
transmission 
Randomized  double-
blind placebo 
community-based  
(multigravidae women) 
Daily oral iron 
(200mg FeSo4)   
Placebo (277 ) 
vs. Iron (273) 
Peripheral malaria at 36 
weeks 
27% vs. 27% 
Placental parasitemia 
8% vs. 8% 
Placental malaria (by 
histology) 
16% vs. 15% 
 
 
Parasite density 
not significantly 
different 
between the 
groups  
14% vs. 17%. 
Only 
multigravidae 
women were 
recruited. 
High proportion 
of women 
treated with IV 
iron was still 
anemic after 
delivery. 
Nacher, 2003 Thailand 
Seasonal 
transmission 
Prospective cohort All women with 
hematocrit<30% 
were given Oral 
600mg FeSo4 and 
5mg folate. 
 
Iron vs. no iron Plasmodium vivax 
(Adj. Hazard ratios) 
1-15d of supplement; 
HR 1.75 (1.14-2.7) 
16-30d of supplement; 
HR 1.7 (1.1-2.6) 
31-60d of supplement; 
HR 1.3 (0.94-1.8) 
>60d of supplement; HR 
0.67 (0.4-1.02) 
Duration of iron 
supplementatio
n was 
prospectively 
divided. 
 
1.7 Laboratory evaluation of malaria infection 
Malaria in pregnancy is usually detected by microscopy of peripheral or placental 
blood smears and histological examination of the placenta.  Microscopy identifies parasite 
species, quantifies parasite density, and is cheaper and highly reproducible [3]. Placental 
histology is the “gold standard” for the diagnosis of malaria at delivery, but is expensive, 
labor intensive, needs expert training and is not frequently available [98]. Histological 
examination of the placenta is the most sensitive method and infection can be classified as 
active, past or chronic [98]. Microscopic examination of peripheral blood usually 
underestimates infection in pregnant women [97, 99, 100] since parasites may sequester in 
the placenta but be absent in peripheral blood [101]. Furthermore, the concentration of 
parasitemia in peripheral blood may just be below microscopic detection. Parasites can be 
detected in the peripheral or placental blood using microscopy with detection limit 
concentration at 20-30parasites/μL blood or at least 0.1% [102]. Other methods include 
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fluorescent microscopy, rapid diagnostic tests (RDTs), rapid dipstick immunoassay and 
polymerase chain reaction (PCR) assays. 
PCR-based methods detect parasite DNA from parasite debris present in the blood. 
PCR can detect infection in peripheral blood when viable parasites are sequestered in the 
placenta [103] or are present at very low levels [104]. It can detect parasites at a 
concentration as low as 2.5 parasites/μL or 0.00005% [105] and is often used as a standard 
against which the diagnostic accuracy of other parasitological methods is determined.  
1.8  Iron deficiency and anemia   
1.8.1 Epidemiology of iron deficiency and anemia 
Iron deficiency (ID), the most common nutritional deficiency affects over 2 billion 
people in the world [106]. Young children and women of child bearing age, particularly 
pregnant women, are commonly and severely affected due to high iron demands of growth 
and pregnancy. The prevalence of anemia among pregnant women is high in developing 
countries where at least 52% are anemic [107] and it ranges from 57% to 86% in SSA 
countries [108, 109]. ID is considered the primary cause of anemia [108]. However, the true 
prevalence of ID is unknown but it is generally assumed that 50% of all anemia cases are 
caused by ID [107].  
ID is not the sole cause of anemia [108]. In Malawian children with severe anaemia 
(Hb <5g/dl), malaria, bacteraemia, HIV, hookworm, deficiency in vitamins A and B12, and 
glucose-6-phosphate dehydrogenase (G6PDH) deficiency were important risk factors and 
not iron or folate deficiency [110]. Among Malawian pregnant women, 23% had iron 
deficiency, 32% had iron deficiency in combination with other nutritional deficiencies, 26% 
had no iron deficiency but other micro-nutrient deficiencies and 20% had no evidence of 
nutrition deficiency [111]. Other causes of anemia include congenital hereditary defects in 
hemoglobin synthesis which cause diseases like thalassaemias and sickle cell and deficits 
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in other nutrients e.g. vitamins A, B12,, and C [107]. Blood loss associated with 
schistosomiasis and hookworm infestation causes both iron deficiency and anemia. HIV 
infection and tuberculosis (TB) are other significant causes of anemia [112, 113]. [112, 114, 
115]Malaria and HIV infections during pregnancy account for 3% to 15% and 12% to 14% of 
maternal anemia in malaria-endemic areas respectively [6].  
1.8.2 Effects of Iron deficiency and anemia on pregnancy  
Clinical manifestations in severe anemia are nonspecific and include fatigue, 
weakness, dizziness and drowsiness. When iron-deficient erythropoiesis occurs, 
haemoglobin concentrations are reduced.  
Prenatal anemia is associated with high maternal and infant mortality and morbidity. 
Iron deficiency anemia increases the risk of preterm labor, and low birth weight [116-119]. 
Both low and high maternal hemoglobin levels have been shown to increase the risk of low 
birth weight and preterm deliveries [120, 121]. All-cause maternal anemia is responsible for 
6.4% of maternal mortality in the African region [122]. However, others have argued that 
there is no strong evidence that maternal anemia per se is associated with increased risk of 
maternal mortality because of confounding by other factors including maternal health status, 
access to and quality of health care services [123].  
1.8.3 Iron in the body systems 
The body requires 20-30mg/day of iron for metabolism including formation of red 
blood cells (rbcs) [124]. Monocytes and macrophages are central in the metabolism of body 
iron (reviewed in [124]). 10% of daily iron needs come from the diet but the majority 
originates from the monocytes or macrophages where iron is recycled from senescent rbcs 
[124]. 70% of total body iron is in blood as hemoglobin in the rbcs, 25% is stored as ferritin 
or hemosiderin in the reticulo-endothelial cells such as macrophages in the liver, bone 
marrow and spleen cells [125]. 5% is present in muscle cells as myoglobin and less than 1% 
is contained in iron-containing enzymes and transport proteins such as peroxidase, catalase, 
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cytochromes and transferrin (iron-carrier protein in plasma). Less than 1% of iron is present 
as “free iron” in the form of labile iron pool (LIP) within and outside cells [87]. Iron introduced 
into the blood circulation during oral or intravenous iron supplementation influences the 
levels of the intracellular and extracellular LIP and believed to have pathological 
consequences when in excess [87]. Intracellular LIP is biologically active and involved in 
cellular processes of metabolism that require iron such as gene regulation, binding and 
transportation of oxygen, regulation of cell differentiation and growth, and cell signaling. The 
ability of iron to reversibly change between ferrous (Fe2+) and the ferric (Fe3+) forms enables 
it to carry electrons to; supply energy to cells, bind to cofactors essential in cell metabolism 
and act as a catalyst for cell reactions such as oxidation, reduction, oxygenation and 
hydroxylation [125].  
Iron becomes toxic in its free form or when present in excess. Hence, labile iron in 
the intracellular LIP or extracellular LIP exists only transiently as a free cation, otherwise it is 
bound by or incorporated into other proteins. The highly reactive nature of iron in the one-
electron reduction-oxidation reactions causes formation of toxic and highly reactive free 
oxygen radicals which damage body cells [126]. The regulation of body iron is complex and 
carefully controlled to preserve body iron needs but prevent toxic levels. In excess, “free 
iron” is scavenged from all body fluids by being incorporated into ferritin molecules for 
storage or other proteins such as serum transferrin which supplies iron to cells, leaving only 
a very low concentration of the “free iron” [reviewed in [127]]. Furthermore, hepcidin peptide 
produced by the liver limits absorption from the gastrointestinal tract and prevents release of 
iron from cells [127]. It is suggested that these processes not only act as protective 
mechanisms against formation of highly reactive free radicals but defend the body against 
invading microbes that require iron for survival [128-130].    
1.8.4 The function of iron in the immune system 
Cell-mediated immunity 
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Both ID and iron overload states have negative effects on immune function and 
response [reviewed in [131]].  
Human and animal studies suggest that some aspects of cell-mediated immune 
response are depressed in iron-deficient states resulting in impairment of ability to kill and 
clear disease causing microorganisms[132] [132, 133]. At least five detrimental effects of ID 
on cell-mediated immune functions or response that are reversible with iron therapy have 
been reported [131]. First, reduced function of polymorph neutrophil cells with associated 
decrease in myeloperoxidase reductase activity [132, 134, 135] result in impaired ability to 
engulf and kill invading microorganism. However, others have reported no difference in the 
function comparing iron-deficient and iron-replete states [136-138].  Second, decreased 
numbers and impaired cytotoxic activity of T-lymphocyte cells have been observed in ID 
compared to iron-replete states [139-144] with one study reporting T-cell proliferation in iron-
deficient women of 40% to 50% of that of iron-sufficient women [145].  However, results 
have not been consistent. Iron supplementation in children for 2 months improved 
hematological parameters but did not improve their T-cell mediated immunity parameters 
[140]. Third, loss of cutaneous hypersensitivity to mitogens and antigens has been 
associated with inadequate iron levels [reviewed in [136]]. Fourth, natural killer cell activity is 
impaired in iron-deficient states [132]. Fifth, secretion and production of cytokines from the 
macrophages which play a key role during inflammatory response to infections and tissue 
injury are reduced [132, 137, 146-148].  
High iron stores in tissues and iron overload in macrophages have negative effects 
on the immune response [149, 150]. HIV-infected persons with high iron levels have been 
found to have increased mortality compared to those with normal or low levels [149, 151-
153]. When iron is in excess, the iron-overloaded macrophages are impaired and their ability 
to kill micro-organisms such as Mycobacteria, Listeria, Candida, Salmonella, Leishmania 
and Plasmodia and viruses is reduced [127, 132, 154-158]. This occurs in part because the 
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production of nitric oxide (NO) by liver cells and macrophages is reduced in excess iron 
[159]. NO molecule is required by macrophages to kill invading micro-organisms [159]. Iron 
blocks gene transcription for NO-synthase enzyme which is responsible for the production of 
cytokine induced NO free radicals in the macrophages [160]. Furthermore, neutrophil 
function is impaired and T-cell proliferation is decreased during iron overload [127, 161, 
162].  
Humoral immunity 
There is a general consensus that humoral immune response is spared in humans 
with iron deficiency though it has been showed to be impaired in iron-deficient animals [137, 
146, 148, 163, 164] and a few studies in iron-deficient children [164, 165]. 
Iron withholding defense mechanism (“Nutritional immunity”) 
Although the immune system is key in fighting and killing infectious pathogens, it is 
suggested that the system is further strengthened by the body’s ability to withhold the 
growth-essential iron from invading pathogens [reviewed in [127, 130]].  The body limits the 
amount of iron available to the pathogens during infection (also known as the “nutritional 
immunity”) through several mechanisms [127, 132]. Cellular and extracellular iron-binding 
proteins such as transferrins and lactoferrin withdraw iron from body fluids. The growth of a 
variety of bacteria and fungi has been shown to be inhibited in vitro by transferrin and 
lactoferrin [166].  Hence, it has been hypothesized that iron supplementation could be 
hazardous in iron deficient individuals at risk of infectious pathogens which require iron for 
replication.  The extent to which iron withholding effect can be equated to nutritional ID is 
still uncertain. While some have argued that further lowering of the saturation of iron in 
transferrin or lactoferrin further enhances immunity [132], others have questioned the 
significance of this hypoferraemia on the growth of microorganisms [133].  
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1.8.5 The function of iron in infections 
Iron is an element that is required by pathogens for replication and growth. In vitro 
studies have shown increased growth of Mycobacterium tuberculosis, Candida, Escherichia 
coli and Staphylococcus aureus with increased iron availability [155, 157, 166, 169-172].  
On the other hand, studies on the effect of ID on infections in humans have often reported 
conflicting results [reviewed in [132]]. Studies in individuals with genetic iron loading 
disorders such as hemochromatosis and sickle cell have reported elevated risk for a range 
of infectious diseases including salmonellosis, pneumonia and Klebsiella infections [167, 
168]. When iron is in excess, the body’s iron withholding defense system can be suppressed 
as the immune system components become overloaded with iron [reviewed in [127]]. In 
addition, host cells that contain iron such as macrophages are damaged if overloaded with 
iron [127]. 
1.8.6 Effect of HIV on anemia and iron metabolism   
Effect of HIV on anemia 
Anemia is a very common complication of HIV infection and its severity is associated 
with advanced stage of disease [173]. In HIV-infected children, anemia was higher 
compared to HIV-uninfected children (Odds Ratio 4.5; 95% CI 2.5-8.3) from both developed 
and developing countries [reviewed in [174]]. The prevalence of anemia varies greatly 
ranging from 1.3% to 95% depending on HIV disease stage, age, sex, pregnancy status, 
and antiretroviral therapy (ART) use among other factors [173]. ART reduces anemia in HIV-
infected persons by inhibiting the progression of HIV disease [175]. The causes of anemia in 
HIV infection are multi-factorial. These causes include drugs such as zidovudine (AZT) and 
CTX; direct effect of HIV on rbcs progenitor cells; nutritional deficiencies such as Vitamin A 
and B; and other infections including HIV-related opportunistic diseases like diarrhoea [176-
179]. Nevertheless, others have suggested that anemia of chronic disease (ACD) is 
common in HIV-infected persons [180]. ACD results from decreased red blood cell formation 
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and is characterized by low serum iron, low iron-binding capacity, increased stored iron and 
elevated serum ferritin [180, 181].   
Pathogenesis and Pathophysiology of anemia in HIV infection 
HIV infection and altered iron metabolism 
Iron metabolism in HIV infection is complex and poorly understood [reviewed in 
[182]]. The extent to which HIV influences iron metabolism depends on the degree of 
immune suppression. Currently, three major pathophysiological pathways that have been 
identified and linked to the development of ACD in HIV-infected persons [reviewed in [124, 
183]]. These pathways are induced by the activated immune response during the chronic 
inflammation caused by HIV and HIV-related infections. 
First, iron retention occurs within the macrophages mediated by cytokines, acute-
phase proteins and free radicals that are released during inflammation [184].  This 
mechanism, central to the development ACD, results in limited availability of iron essential 
for proliferation and differentiation of erythroid progenitor cells causing reduced production 
of red blood cells [131]. Cytokines such as interferon-gamma (IFN-γ), interferon-alpha (IFN-
α), tumor necrosis factor-alpha (TNF-α), and interleukin-1 (IL-1); acute-phase proteins from 
the liver, and macrophage-derived free radicals alter iron metabolism of the macrophages 
by modulating iron uptake and release [124]. TNF-α, IL-1, and IL-6 induce iron retention in 
macrophages by inducing transcription and translation of iron-storage protein (ferritin) gene 
[185-189]. At the same time, these cytokines down-regulate expression of transferin 
receptors (TfRs) gene inhibiting iron uptake by other body cells thereby allowing iron to be 
sequestration in macrophages [154, 190]. However, others have found no association 
between IFN-γ and iron disturbance in ACD of HIV infection [180]. Second, cytokines and 
acute-phase proteins inhibit proliferation and differentiation of erythroid progenitor cells in 
HIV infection [191, 192]. Mechanisms involved include down-regulation of erythropoietin-
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receptor expression and other pro-hematopoietic factors such as stem cell factor on 
progenitor cells thereby blunting progenitor cells response to erythropoietin in HIV infection; 
direct toxic effects of cytokine induced radicals such as nitric oxide (NO) which inhibit 
erythroid progenitor cell proliferation; binding of acute-phase proteins to TfRs inhibiting TfR 
mediated iron uptake into erythroid progenitor cells blocking growth and differentiation [124]. 
Third, ACD is associated with impaired formation and activity of erythropoietin hormone.  
TNF-α and IL-1 induce formation of toxic free radicals which damage erythropoietin 
producing cells and inhibit erythropoietin formation [193]. Furthermore, toxic radicals 
damages erythrocyte membranes increasing their susceptibility to phagocytosis by 
macrophages. Injection of high doses of TNF-α in mice resulted in shortened half life of 
erythrocytes and faster clearance of from circulation through phagocytosis [194].  
Iron accumulation in body tissues and failure to utilize iron for red blood cell 
production can occur due to HIV or HIV-related infections [151, 182, 195, 196]. Hence, 
routine provision of iron supplements to HIV-infected pregnant women irrespective of 
the cause of anemia may facilitate iron availability to invading microorganisms such 
as malaria parasites.  
1.8.7 Iron supplementation in pregnancy 
The body iron requirement for an average pregnancy is about 1000mg and this 
exceeds the iron stores of most women [197, 198]. Approximately 200 mg is shed via the 
gut, urine, and skin [199]. Iron from diet coupled with that mobilized from body stores, is 
usually insufficient to meet the demands of pregnancy. This is true even though the 
bioavailability of iron from the gastrointestinal tract is moderately increased during 
pregnancy and menstrual iron loss ceases. Therefore, routine iron supplementation during 
pregnancy is recommended even in non-anemic women [106].  
Benefits of iron supplementation in pregnancy 
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 Iron supplementation during pregnancy improves hematological and 
biochemical parameters such as hemoglobin concentration and iron status biomarkers 
including serum ferritin and sTfRs [reviewed in [200]]. Women supplemented with iron have 
higher mean hemoglobin concentration and higher levels of iron compared to women on 
placebo [201, 202] . However, despite numerous studies over the years, the effect of routine 
antenatal iron supplementation on clinically important maternal and infant outcomes such as 
LBW remains unclear [200]. The observed positive impact of iron supplementation in RCTs 
is usually not replicated in the routine iron supplementation programs aimed at preventing 
iron deficiency and anemia [203]. This could be due to the fact that the investigators have no 
control over the study participants. Other problems include; inadequate and irregular 
supplies, compliance, poor quality of supplements, lack of health education, poor or no 
attendance at antenatal clinic, first antenatal visit occurring late in pregnancy and in some 
cases poor training and adherence to protocol by the health care providers [204-207].   
Harmful effects of iron supplementation in pregnancy   
A recent review of studies reporting the effect of iron supplementation on pregnancy 
outcomes suggests that there is no strong evidence that routine iron supplementation 
improves the health outcomes for the women and babies [200, 208]. For example, 
significantly more dead infants were observed in a Finland study among women who 
received routine iron supplementation compared to women who were selectively 
supplemented [209].  In a more recent placebo-controlled study in Iran among women with 
hemoglobin concentration ≥ 13g/dl, women who received routine iron supplementation were 
more likely to have hypertension and small-for-gestation age (SGA) babies compared to 
women in the placebo group [210]. In contrast, in a North Carolina study among low-income 
women with hemoglobin concentration 11g/dl and ferritin ≥ 40μg/L, supplemented group had 
higher mean birth weight and less preterm deliveries [211]. However, the prevalence of SGA 
babies or third trimester iron status was not different between the two groups. Although 
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iron supplementation may improve hemoglobin concentration and pregnancy 
outcomes in some pregnant women, it may be hazardous in some women or for some 
pregnancy outcomes. 
1.8.8 Diagnosis of anemia and iron deficiency  
Anemia is defined as a low hemoglobin concentration (Hb) in the circulating blood 
[212]. Hb of less than 11g/dl is defined as anemia in pregnant women [107] and is also 
classified as severe (< 6g/dl) or moderate (≤ 8g/dl) [213].  
Serum ferritin and soluble transferrin receptor (sTfR) are surrogate markers of stored iron 
and are used to estimate the body iron levels. The gold standard method is pathological 
examination of bone marrow aspirates. However, because it is very invasive and painful, 
bone marrow aspiration is rarely used. Interpretation of iron biomarkers is very complex 
especially when there is inflammation. Serum ferritin increases in acute phase of 
inflammation. Measurement of Hb, ferritin and sTfR, complemented with indicators of acute 
and chronic infections such as C-Reactive Protein (CRP) for acute infections or alpha-1 
glycoprotein (AGP) for chronic infections, is the best procedure for evaluating iron status 
[212]. There are no clear cut off values for ferritin but they usually range between 10 and 30 
mg/L [212]. Other investigators have suggested that sTfR/log ferritin (TfR-F index) is the 
best indicator of iron deficiency especially in areas with high prevalence of infections [214, 
215]. 
1.9 Summary of background 
Malaria and anemia in HIV-infected pregnant women cause significant peri-natal 
morbidity and mortality. It is imperative to ensure that the prevention and control 
interventions of these health problems targeting this population are effective and based on 
empirical evidence. There are gaps in our knowledge concerning the role that some factors 
(or exposures) play on these health problems in this high risk population. This dissertation 
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examined malaria and anemia in HIV-infected pregnant with the purpose of generating 
useful data for public policy makers for their consideration as they develop and improve 
programs aimed at reducing or preventing malaria and anemia in HIV-infected pregnant 
women.  
  
CHAPTER 2: SPECIFIC AIMS 
2.1 Specific aim 1 
To examine the effectiveness of Cotrimoxazole (CTX) with or without sulfadoxine-
pyrimethamine for intermittent preventive treatment of malaria (SP-IPT) compared to 
SP-IPT only at reducing malaria infection and anemia in HIV-infected pregnant women 
in Malawi 
2.1.1 Hypotheses 
The hypotheses of this study include: 
a. Cotrimoxazole with or without SP-IPT is associated with low prevalence of malaria 
infection compared to SP-IPT only in HIV-infected pregnant women  
b. Cotrimoxazole with or without SP-IPT is associated with increased prevalence of 
maternal anemia and reduced hemoglobin concentration compared to SP-IPT only in 
HIV-infected pregnant women 
2.1.2 Rationale 
WHO recommends that HIV-infected pregnant women must receive at least 3 doses of 
sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria during 
pregnany (IPTp) but those taking daily cotrimoxazole (CTX) as prophylaxis for opportunistic 
infections should not be given SP-IPTp to avoid adverse drug toxicity since both drugs 
contain sulphur and are anti-folates [216]. Countries like Uganda and Malawi currently 
recommend that all HIV-infected pregnant women should receive daily CTX to prevent 
malaria during pregnancy [217]. The efficacy, effectiveness and safety of SP-IPTp during 
pregnancy has been evaluated in many studies. However, the efficacy, effectiveness  and 
safety of CTX use to prevent malaria compared to the standard SP-IPT has not been 
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assessed in pregnant women. HIV-infected pregnant women are at an increased risk of 
frequent and severe disease and adverse effects such as anemia, preterm and low birth 
weight deliveries compared to HIV-uninfected pregnant women [reviewed in [48]]. Therefore, 
it is important to use efficacious and effective drugs based on empirical evidence if malaria 
and its complications are to be successfully prevented and controlled in this high risk 
population. This study will provide the lacking data on the effectiveness of cotrimoxazole in 
preventing malaria compared to SP-IPTp. Findings would assist policy makers to formulate 
policies that work for HIV-infected pregnant women on daily cotrimoxazole prophylaxis.       
2.2 Specific aim 2 
To determine the association between submicroscopic malaria infections and 
maternal anemia in HIV-infected pregnant women in Malawi 
2.2.1  Hypothesis 
Maternal anemia is increased in HIV-infected pregnant women with submicroscopic 
malaria infection compared to HIV-infected pregnant women without malaria infections. 
2.2.2 Rationale 
A large number of pregnant women in malaria-endemic areas, ranges between 18% 
and 55%, harbor submicroscopic malaria i.e. parasite DNA is detected in their blood but 
parasites are not seen on microscopic examination [24, 41, 61-64]. Little is known about the 
factors that influence the occurrence of submicroscopic malaria [65] and its clinical 
importance on maternal or birth outcomes in pregnant women is unclear. While some 
studies in pregnant women of unknown HIV status have found an association between 
submicroscopic malaria infections and maternal anemia or LBW [41, 72, 73], others have 
not [24, 61, 62, 218]. Immunity to malaria is impaired in HIV infection [51, 52, 219, 220], 
hence, submicroscopic malaria could be of clinical significance in HIV-infected pregnant 
women. No published study has reported on the factors or effects that are associated with 
submicroscopic malaria infection in HIV-infected pregnant women. This study will provide 
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information on important predictors of submicroscopic malaria infection and may assist 
clinicians in identifying women at risk. Results would also elucidate whether submicroscopic 
infections are of clinical significance in HIV-infected pregnant women. This information could 
assist policy makers in improving strategies to further reduce the incidence and adverse 
effects of malaria in this population. 
2.3 Specific aim 3 
To investigate the associations of iron supplementation and iron deficiency with 
malaria infection in HIV-infected pregnant women in Malawi.  
2.3.1 Hypothesis 
The hypotheses of this study include: 
a. The prevalence of malaria infection are higher in HIV-infected pregnant women 
who received iron supplementation during pregnancy than those who did not. 
b. The prevalence of malaria infection increases as the duration of iron 
supplementation increases in HIV-infected pregnant women 
c. The prevalence and density of malaria infection is lower in HIV-infected pregnant 
women with iron deficiency compared to iron replete women. 
2.3.2 Rationale 
Evidence suggests that iron supplementation in individuals living in malaria-endemic 
areas could increase the risk of malaria [221-223].  Animal studies have shown that 
replication of malaria parasites is increased in iron replete mice compared to iron deficient 
mice [82, 224]. Currently, there is a great concern that the standard practice, of providing 
iron supplements to all pregnant women living in areas where prevalence of anemia is high 
irrespective of their iron level status, as recommended by the World Health Organization 
(WHO), could be harmful in malaria-endemic areas [107]. Few published studies have 
reported on the effects of iron on malaria in pregnant women and none has been done in 
HIV-infected pregnant women [91-94]. Iron supplementation could be more harmful in HIV-
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infected pregnant women compared to HIV-uninfected pregnant women. First, HIV-infected 
pregnant women have low malaria immunity compared to HIV-uninfected pregnant women 
[51, 52, 220]. Second, studies have found that iron accumulation in body tissues and 
abnormal iron metabolism due to chronic HIV infection occur in HIV-infected individuals 
[225-227]. High iron levels are associated with microbial infections and increased mortality 
in HIV-infected individuals [151, 153, 182, 195]. This study will provide information on 
whether routine iron supplementation is associated with increased malaria infection or not 
and whether iron deficiency confers protection from malaria infection in HIV-infected 
pregnant women.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 3: RESEARCH DESIGN AND METHODS 
3.0 Overview of methods 
This chapter describes the study design and methods applied to the 3 specific aims of 
the three studies for this dissertation.  
For aim 1, logistic regression model was used to assess the association of 
cotrimoxazole (CTX)  with or without SP-IPTp with microscopic or PCR-detected malaria 
infections in HIV-infected pregnant women. Log-binomial regression model was used to  
assess the association between cotrimoxazole with or without SP-IPTp and maternal  
anemia.  Poisson regression model with robust variance estimator was used to confirm 
estimates from log-binomial regression models. Linear regression model was used to  
assess the association between cotrimoxazole with or without SP-IPTp and maternal  
hemoglobin concentration.  
For aim 2, Log-binomial regression model was used to assess the association between 
submicroscopic malaria infection and maternal anemia. Linear regression model was used 
to assess the association between submicroscopic malaria infection and maternal 
hemoglobin concentration.  
For aim 3, Logistic regression model was used to assess the relationship between iron 
supplementation or iron deficiency and malaria infection.  
3.1 Study design 
The data used in the analyses for the 3 specific aims under investigation are from a 
cross-sectional study entitled “Iron supplementation in HIV-infected pregnant women study” 
(IHIP study). The overall goal was to investigate the benefits and risks of iron 
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supplementation on maternal morbidities among HIV-infected pregnant women. This section 
describes the study site, population and data collection methods that were used in the IHIP 
study and were the same for all the three specific aims of this dissertation. 
3.1.1 Study site 
The IHIP study was conducted at Thyolo district hospital antenatal clinic in southern 
Malawi. The district covers an area of 1,715 km² with an estimated total population of 
587,455 of whom 52% are females [228]. The district is mainly located in the country’s low 
land zone where malaria transmission is perennial but increases during the warm, rainy 
season (December-April) when mosquito breeding is high [229]. P. falciparum causes 95% 
of malaria infections in this area and the prevalence of anemia among pregnant women in 
Thyolo district is 47% and is higher during the rainy season [229, 230]. The district hospital 
provides free antenatal services and has a well established prevention of mother-to-child 
transmission of HIV (PMTCT) program operated in collaboration with Medecins Sans 
Frontieres of Luxembourg (MSF-L). The hospital has a flow cytometer and HIV-infected 
pregnant women get CD4 count measurements. As part of PMTCT program, every woman 
is provided with a single dose of niverapine to be taken during labor.  
3.1.2 Study population 
All HIV-infected pregnant women with at least 34 weeks of gestation attending routine 
antenatal care services at Thyolo district hospital antenatal clinic previously tested positive 
for HIV infection were eligible for the study. Women with immediate life-threatening medical 
or obstetric conditions or those less than 15 years were excluded. At the time of seeking 
ethical approval for this study, women less than 15 years of age required additional consent 
from their traditionally-accepted guardians. However, the guardians do not accompany the 
women to the antenatal clinics. 
 
31 
 
3.1.3 Data collection 
Recruitment 
All consenting HIV-infected pregnant women were eligible for enrollment. A total of 
1,142 HIV-infected pregnant women were recruited between December 2005 and July 2009. 
Figure 3.1 summarizes the recruitment protocol for the IHIP study. Nurses providing routine 
antenatal care informed HIV-infected women about the study and invited them to participate. 
Consenting women were then referred to research nurses for an interview using a 
standardized questionnaire. Information on socio-demographics (age, marital status, level of 
education, place of residence, occupation, house structure building materials), obstetric 
history (gravidity, year/date of last delivery, the occurrence of obstetric complications during 
the index pregnancy) and medical history (occurrence of infections and/or other diseases 
during the index pregnancy, the use of antiretroviral therapy (ART), use of any other 
medications) was collected.  Weight, height and mid-upper arm circumference (MUAC) were 
obtained to estimate nutritional status. Women were also examined and classified using 
WHO HIV disease clinical staging by the research nurses. Temperature, pulse and blood 
pressure measurements were also taken.  
 
 
 
 
 
 
 
 
 
 
 
Pregnant women 
receive HIV- VCT at 
Antenatal Clinics 
 
HIV+ women with OI or 
CD4 cell count <200 
receive ART 
ANC nurses seek 
consent from HIV+ 
women at ≥34 weeks 
gestation. 
Consenting women 
referred to research 
nurses   
Research nurses  
 Perform interviews 
 Perform physical 
examination 
 Perform venous 
blood draws 
 Collect stool and 
urine samples 
 
 
ENROLLMENT PERIOD PRE-ENROLLMENT PERIOD 
Abbreviations: HIV+=HIV-infected, VCT=voluntary counseling and testing, OI= Opportunistic infections, 
ART=Antiretroviral Therapy, ANC=Antenatal Clinic.  
Figure 3.1: Enrollment protocol for IHIP study 
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Laboratory procedures  
Detection of malaria infection  
Malaria infection was detected using two methods. First, two well trained laboratory 
technicians performed light microscopy at Thyolo district hospital. Thick blood smears were 
prepared stained using Field’s stain A and B as described in [[102]]. A thick blood film was 
first dipped in Field’s stain A for 5 seconds and rinsed in tap water for 10 seconds, then it 
was dipped in Field’s stain B for 5 seconds and rinsed in tap water for 10 seconds. The slide 
was then air dried and examined under a microscope using a magnification of 100 x oil 
immersion objective to detect and quantify parasites.  Asexual forms of malaria parasites 
were counted per 200 leukocytes. A blood film was considered negative if no parasites were 
detected per 200 leukocytes. To estimate the parasite density per microlitre of blood, the 
number of parasites counted was multiplied by 40 under the assumption that a standard 
leukocyte count is 8,000 per microlitre of blood. Any discrepancies were resolved by an 
experienced microscopist. Second, real-time polymerase chain reaction (RT-PCR) for 
malaria parasite DNA were conducted at the University of North Carolina at Chapel Hill 
(UNC-CH). Two blood spots were made on a filter paper, air dried and packed in ziplock 
bags with dessicant and then couriered to UNC-Chapel Hill laboratory. Malaria parasite DNA 
was extracted and recovered in 200 µl of elution buffer from the filter papers using an 
invitrogen PureLink Genomic DNA kit (Invitrogen, Carlsbad, USA) as per manufacturer’s 
instructions. PCR amplification of the malaria parasite DNA was done in two steps using a 
pooling method as described in [231] with use of 18s rRNA forward primer 
(sequence:5’_GTTAAGGGAGTGAAGACGATCAGATA), 18s rRNA reverse primer 
(sequence:3’_ AACCCAAAGACTTTGATTTCTCATAAG) and 18s rRNA minor-groove 
binding probe (VIC-TCG TAA TCT TAA CCA TAA AC-MGBNFG). In the first step, pools of 4 
from the samples were tested. DNA amplification of each pool was performed using 7300 
Real-Time PCR system thermal cycler (Applied Biosystems, Foster city, CA). Each 
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amplification reaction was done in a volume of 25 µl comprised of PCR buffer (ABI TaqMan 
mastermix; Qiagen), 18s rRNA forward primer, 18s rRNA reverse primer, 18s rRNA minor-
groove binding probe, and DNA extract from the sample to be tested. In the second step, 
each sample in any positive pool was individually tested. P. falciparum strain 3D7 and 
Sigma water were used as positive and negative controls respectively in all steps. Detection 
and analysis of results were performed using the 7300 Real-time detection system and 
sequence detection software version 1.3.1 (Applied Biosystems, Foster city, CA). 
Hemoglobin concentration 
Hemoglobin concentration (Hb) measurement was performed on whole blood using a 
Hemocue hemoglobinometer (HemoCue AB, Ängelholm, Sweden). 
Stool and urine examination 
Stool samples were examined for helminth infection. First, macroscopic examination 
for the presence of pus, mucus, blood or worms was done. Samples were then prepared for 
microscopic examination using saline wet mount for detection of hookworm ova and cysts 
detection, followed by iodine wet mount for identification of cysts. Urine samples were 
examined by light microscopy for the presence of Schistosoma hematobium parasites.  
CD4 T-cell count 
Whole blood was stained with anti-CD4 within 48 hours of collection and T-
lymphocyte subset counting was performed using the FACS count flow [70]cytometer 
(Becton-Dickinson, San Jose, CA).  
Measurement of iron biomarkers and C-reactive protein 
Biochemical biomarkers of iron were assessed for the first consecutive 455 women that 
were recruited in the study. Serum ferritin and serum iron were measured using ELISA kits 
(Roche Diagnostics, Switzerland). Serum transferrin receptors (sTFR) concentration was 
measured using an enzyme immunoassay (Ramco Laboratories, Texas, USA). C-reactive 
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protein (CRP) concentrations were measured by ELISA (Immuno-Biological Laboratories 
[IBL], Hamburg, Germany). 
3.1.4 Data cleaning and quality control 
The Microsoft Access database was reviewed for completeness from July  to 
September 2009. Any discrepancies and abnormal values were checked  with the 
questionnaire records and corrections were made wherever necessary. 
3.2 Methods for Aim 1 
3.2.1 Study site, population and data collection 
These are the same as described under the study design section 3.1 above. 
3.2.2 Classification of exposure 
The main exposure for aim 1 was antimalarial drug exposure during pregnancy. This 
was categorized as CTX plus SP-IPTp, CTX only, SP-IPTp only and None. Drug exposure 
was self-reported and antenatal records were checked to verify that a prescription was 
made. 
3.2.3 Classification of outcomes 
Two main outcomes considered in this study included: 
1. Malaria infection – this outcome was analyzed in two ways as 1) Microscopic malaria 
infection if a woman had a positive malaria result on microscopy and was analyzed as a 
binary variable 2) PCR-based malaria infection defined as a positive RT-PCR result for 
malaria and was analyzed as a binary variable.  
2. Maternal anemia - this was defined as hemoglobin concentration level <11g/dl and was 
analyzed as a binary variable. Hemoglobin concentration was also analyzed as a 
continuous variable. 
 
 
35 
 
3.2.4 Statistical analysis 
Univariate analyses 
The distributions of categorical variables, such as gravidity, bed net use, ART use, 
socio-economic status (SES), malaria infection, HIV clinical stage, anemia and main 
exposure were described using frequencies and proportions.  If there was insufficient data in 
some of the categories, adjacent categories were combined. Distributions of continuous 
variables, such as age, CD4 count, number of antenatal visits, body mass index (BMI) and 
mid-upper arm circumference (MUAC) were examined using mean and standard deviation 
or median and range for normally distributed data and non-normally distributed data 
respectively. The data was examined for outliers and abnormal values which were corrected 
if inconsistent with raw data. Cut-off points for continuous variables were based on literature 
review or the distribution of the data.    
Bivariate analyses 
These were used to compare characteristics of the study population across the 
levels of main exposure. The associations between main exposure or outcomes and 
covariates were also examined in bivariate analyses. Pearson chi-square test, analysis of 
variance (ANOVA) or student’s t-test and Kruskal-Wallis test or Wilcoxon rank sum test were 
used to compare between outcomes or exposure and categorical variables, normally 
distributed variables and non-normally distributed variables respectively.  
Evaluation of Linearity assumption for continuous variables 
All continuous covariates were tested for the assumption of linearity to determine 
whether the covariate could be used as a continuous or categorical variable in the 
multivariate analyses. Each continuous variable was categorized, then the Odds ratio (OR) 
or prevalence ratio (PR) for each category and the dichotomous malaria outcome or 
maternal anemia was estimated. The variable was deemed to meet the assumption of 
linearity if the incremental increase, decrease or constant OR (or PR) was observed across 
36 
 
levels of the covariate. This meant that the covariate could be used as a continuous varibale 
in multivariate models. If the linearity assumption was not met, the covariate was entered in 
the model as a categorical variable. Age, BMI and CD4 count did not meet the assumption 
of linearity and were therefore analyzed as categorical variables in multivariate models of 
the association between anti-malarial drug exposure and malaria infection. MUAC met the 
linearity assumption and was therefore analysed as a continuous variable in multivariate 
models.  
Evaluation of Effect Measure Modification 
Only covariates in unblocked backdoor pathways between antimalarial drug 
exposure and malaria infection or anemia in the directed acyclic graphs (DAGs) in Figures 
3.2 and 3.3 were considered as potential effect measure modifiers. Based on literature 
review, it has been suggested that the host immunity possibly modifies the efficacy of 
antimalarial drugs on malaria [232]. Hence, we examined the potential effect measure 
modification (EMM) of the association by age, gravidity and CD4 count which are associated 
with antimalarial immunity [39, 51, 233].  Bed net use and SES were also assessed for EMM 
since they were in unblocked backdoor pathways (Figure 3.2). We examined the potential 
EMM of the association between antimalaria drug exposure and maternal anemia by 
gravidity, intestinal parasitic infection, BMI, CD4 count and iron supplementation. The effect 
measure modification was assessed using both Breslow-Day test of homogeneity of the 
odds ratio across covariate strata in tabular analysis and Wald test p-value of the interaction 
term in simple logistic model that included the main exposure, covariate and the interaction 
term. Likelihood ratio (LR) test of an interaction term between the main exposure and the 
potential effect measure modifier in logistic regression analysis was also used. The full 
model (one with the interaction term) was compared to reduced model without the 
interaction term; 
Full model: logit[p(Y=1)] = β0 + β1 (antimalarial drug) + β2 (potential modifier)  
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+ β3 (antimalarial drug*potential modifier) 
Reduced model: logit[p(Y=1)] = β0 + β1 (antimalarial drug) + β2 (potential modifier)  
EMM was considered to be present if the Brelow-Day test p-value was <0.20 since 
this test has low statistical power or if the Wald test p-value of the interaction term was 
<0.05. If a LR test p-value for the interaction term was <0.20 EMM was considered present. 
When EMM was present, estimates of the association between antimalarial drug and 
malaria infection were reported for each level of the effect measure modifier.  
Evaluation of confounding 
Directed acyclic graphs were used to identify potential confounders for the 
association between antimalaria drug exposure and malaria infection or anemia (Figure 3.2 
and Figure 3.3). Covariates that were not effect measure modifiers were tested for 
confounding. A covariate was considered as a potential confounder if it was not affected by 
the outcome or exposure, was in an unblocked backdoor path and adjustment of which 
would not cause a spurious association between two other variables (i.e not a collider). The 
covariate was also associated with both the exposure and the outcome. An OR above 2.5 or 
below 0.50 was considered as a strong association, an OR between 0.50 and 0.90 or 
between 1.1 and 2.5 was considered a weak association. A backward elimination strategy 
was applied to select the best model that explained the association between antimalarial 
drug exposure and malaria infection or anemia. The absolute change in estimate criterion 
was used to assess strength of confounding. The crude log OR estimate from the full model 
was compared to the log OR from the adjusted model. If the adjustment of the covariate 
resulted in ln[ORcrude/ORadjusted]*100 >10% then the covariate was retained in the model.  
Covariates that caused the least change in estimate were sequentially dropped from the 
model until all the covariates left in the model caused a change in estimate of at least 10%. 
If EMM was present, change in estimate was assessed for each stratum specific estimates. 
Based on DAG analysis, age, gravidity, number of antenatal visits, CD4 count,bed net use 
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and SES were included as potential confounders for the association between antimalarial 
drug exposure and malaria infection. Antiretroviral drug use (ARV) could not be entered in 
the same model with CD4 count or HIV disease clinical stage since these variables were 
strongly associated. Age, gravidity, number of antenatal visits, CD4 count and BMI were 
included as potential confounders for the association between antimalaria drug exposure 
and maternal anemia. Iron supplementation and number of antenatal visit were not included 
in the same model since they were strongly associated. BMI and MUAC were not be 
included in the same model since each could be used as a proxy for nutritional status.   
Multivariate analyses 
Logistic regression was used in multivariate analyses of the association between 
antimalarial drug exposure and malaria infection [234]. The full model included the outcome, 
main exposure and all the potential confounders. The beta coefficients for the model were 
estimated using the Maximum likelihood method. The equation for the full model used is 
shown below: 
Logit[p(Y=1│X)] = β0 + β1 X1 + β2 X2 + ………….+ βkXk 
Where Y is the outcome variable (malaria infection) 
X is the vector representing the independent varaiables in the model 
X represents the independent variables including antimalarial drug exposure  
β represents the parameter estimating the effect of a covariate in the model 
Log-binomial regression was used in multivariate analyses of the association 
between antimalarial drug exposure and maternal anemia [235-237]. Poisson regression 
model with robust varaience estimator was used to confirm the estimates obtained from the 
log-binomial  regression model [235, 238]. The beta coefficients for the model were  
estimated using the Maximum likelihood method. The equation for the full model used is 
shown below: 
P(Y=1│X) = β0 + β1 X1 + β2 X2 + ………….+ βkXk 
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Where Y is the outcome variable (maternal anemia) 
X is the vector representing the independent variables in the model 
Xk represents the independent variables  
β represents the parameter estimating the effect of a covariate in the model 
Linear regression model was used in multivariate analyses of the association 
between antimalarial drug exposure and maternal hemoglobin concentration. The equation 
for the full model used is shown below: 
Y = β0 + β1 X1 + β2 X2 + ………….+ βkXk 
Where Y is the outcome variable (hemoglobin concentration level in g/dl) 
Xk represents the independent variables  
β represents the parameter estimating the effect of a covariate in the model 
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3.3 Methods for Aim 2 
3.3.1 Study site, population and data collection 
These are the same as described under the study design section 3.1 above. 
3.3.2 Classification of exposure 
The main exposure for aim 2 was malaria infection. The main exposure was analyzed 
in two ways 1) as a categorical variable (Microscopic, Submicroscopic, and None) 2) as a 
binary variable  (Submicroscopic and None) in the analyses of predictors of submicroscopic 
malaria infection. Microscopic malaria infection was defined as a positive microscopy result. 
Submicroscopic malaria infection was defined as a RT-PCR positive result and a negative 
microscopy result.  
3.3.3 Classification of outcomes 
Maternal anemia was analyzed in two ways: 1) as a binary variable with anemia 
defined as hemoglobin concentration of <11g/dl. 2) as a continuous variable (hemoglobin 
concentration).    
3.3.4 Statistical analysis 
Univariate analyses 
This was done as described for aim 1 in section 3.2.4.1 above. 
Bivariate analyses and evaluation of linearity  
This was done as described for aim 1 in section 3.2.4.2 above. 
Evaluation of Effect Measure Modification 
Covariates in unblocked backdoor pathways between submicroscopic malaria and 
maternal anemia in the DAG Figures 3.4 were assessed for EMM.  The Breslow-Day test for 
homogeneity was used to compare the effect estimate across strata of each covariate 
evaluated at significance level of at least 0.20.  Likelihood ratio (LR) test of an interaction 
term between the main exposure and the potential effect measure modifier in regression 
analysis was also used to assess EMM as described for aim 1 in section 3.2.4.3 above.  
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Evaluation of confounding 
This was done as described for aim 1 in section 3.2.4.4 above. The DAG was used 
to identify potential confounders for the association between submicroscopic malaria 
infection and maternal anemia (Figure 3.4) [239] using DAG criteria [240, 241]. Age, 
gravidity, bed net use, CD4 count, SES , season of enrolment, CTX intake and BMI were 
considered as potential confounders for the association between submicroscopic malaria 
infection and anemia. Iron supplementation and intestinal parasitic infections were not 
included as a confounders since they were deemed not to be associated with malaria 
infection in the DAG. ARV intake and WHO HIV disease clinical stage were not included in 
the model with CD4 count variable since they were strongly associated. 
Multivariate analyses 
Log-binomial regression was used in multivariate analyses of the association 
between submicroscopic and maternal anemia [235-237] and Poisson regression model 
with robust variance estimator was used to confirm the estimates obtained from the log-
binomial  regression model [235, 238]. Linear regression model was used in multivariate 
analyses of the association between submicroscopic malaria infection and maternal 
hemoglobin concentration. Details of the regression models are as described in aim 1 
section3.2.4.5. 
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Figure 3.4: Directed Acyclic Graph for the association between submicroscopic malaria and maternal anemia 
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3.4 Methods for Aim  3 
3.4.1 Study site, population and data collection 
These are the same as described under the study design section 3.1 above. 
3.4.2 Classification of main exposures 
The main exposures considered for aim 3 included:  
1. Iron supplementation- analyzed as a binary variable (Yes/No).  
2. Duration of iron supplementation- analyzed as a categorical variable ( 0 days, 1-15 
days, 16-30 days, 31-60 days and > 60 days). Since there are no standard cut-off points 
for duration of iron supplementation, these cut-off points were chosen to compare our 
results with similar studies [92].   
3. Iron deficiency- defined as ferritin concentration <30 μg/L for women with CRP of ≤ 8.2 
mg/L (i.e. iron deficiency in the absence of inflammation) or ferritin <70 μg/L for women 
with CRP of > 8.2 mg/L (i.e. iron deficiency in presence of inflammation). There no 
standard cut-off points for ferritin in presence of inflammation. However, these definitions 
were selected to compare our results with studies that have used similar cut-off points 
[95, 96].    
3.4.3 Classification of outcomes 
Malaria infection was the main outcome for aim 3 – this was analyzed in two ways as 
1) Microscopic malaria infection defined as a positive malaria test on microscopy analyzed 
as a binary variable (Yes/No)  2) PCR-based malaria infection defined as a positive PCR 
test for malaria analyzed as a binary variable (Yes/No).  
3.4.4 Statistical analysis 
Univariate analyses 
This was done as described for aim 1 in section 3.2.4.1 above. 
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Bivariate analyses and evaluation of linearity 
This was done as described for aim 1 in section 3.2.4.2 above. To assess the dose-
response relationship between duration of iron supplementation and malaria infection, the 
duration of iron supplementation was coded using incremental coding with women in the 1-
15 days as a reference category. 
Evaluation of Effect Measure Modification 
Covariates in unblocked backdoor pathways between iron supplementation or iron 
deficiency and malaria infection in the DAG Figures 3.5 and 3.6 were assessed for EMM.  
The Breslow-Day test for homogeneity was used to compare the effect estimate across 
strata of each covariate evaluated at significance level of at least 0.20.  Likelihood ratio (LR) 
test of an interaction term between the main exposure and the potential effect measure 
modifier in regression analysis was also used to assess EMM as described in aim 1 in 
section 3.2.4.3 above.  
Evaluation of confounding 
This was done as described for aim 1 in section 3.2.4.4 above. DAGs in figures 3.5 
and 3.6 were used to identify potential confounders for the association between iron 
supplementation or iron deficiency and  malaria infection. Age, gravidity, bed net use, SES , 
and season of enrolment were considered as potential confounders for the association 
between iron supplementation and malaria infection. Age, gravidity, bed net use, SES , 
intestinal infections, CD4 cell count and BMI were considered as potential confounders for 
the association between iron deficiency and malaria infection.  
Multivariate analyses 
Logistic regression was used in multivariate analyses of the association between iron 
supplementation or iron deficiency and and malaria infection [234]. Details of the regression 
models are as described for aim 1 in section 3.2.4.5 above. 
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CHAPTER 4: MARKED REDUCTION IN PREVALENCE OF MALARIA AND ANEMIA IN 
HIV-INFECTED PREGNANT WOMEN TAKING COTRIMOXAZOLE WITH OR WITHOUT 
SP-IPT IN MALAWI 
Abstract 
Background: The effectiveness of cotrimoxazole (CTX) compared to sulfadoxine-
pyrimethamine (SP) to prevent malaria in HIV-infected pregnant women (IPTp) is unknown. 
We examined the effectiveness of CTX with or without SP-IPTp versus SP-IPTp only at 
reducing the prevalence of malaria and anemia in HIV-infected pregnant women. 
Methods: From December 2005 to July 2009, 1,142 HIV-infected pregnant women were 
recruited in a cross-sectional study at Thyolo district hospital, Malawi. Peripheral blood was 
tested for malaria infection and hemoglobin concentration. Data on the use of anti-malaria 
interventions and other potential risk factors was collected. When policy on CTX prophylaxis 
was introduced at the hospital, implementation problems resulted in some women receiving 
both CTX and SP-IPTp.  
Findings: Data were available from 1,121 of 1,142 enrolled women regarding intake of CTX 
and/or SP-IPTp. Of these, 49.7%, 29.8%, and 15.4% reported taking SP-IPTp only, CTX 
only and SP-IPTp plus CTX respectively. Compared with taking SP-IPTp only, those taking 
SP-IPTp plus CTX and CTX only were less likely to have microscopic (OR 0.09; 95%CI 
0.01-0.66 and 0.43; 95%CI 0.19-0.97 respectively) or PCR-detected malaria infections (OR 
0.24; 95%CI 0.10-0.62 and 0.44; 95%CI 0.25-0.78 respectively) or anemia (PR, [95% CI]: 
0.67, [0.54-0.83] and 0.72, [0.61-0.83] respectively). 
Conclusion: In HIV-infected pregnant women, cotrimoxazole with or without SP-IPTp 
reduces the risk of malaria and anemia. Longitudinal studies are needed to assess the 
effects of these drugs on birth outcomes and toxicity. 
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Introduction 
Malaria in pregnancy is a preventable cause of significant maternal and peri-natal 
morbidity and mortality in sub-Saharan Africa [2]. HIV infection increases the risks of 
placental and peripheral malaria, high density parasitemia and febrile malaria illness among 
pregnant women [22, 48-50]. HIV-infected pregnant women are particularly at an increased 
risk of premature delivery, severe anemia, delivery of low birth weight infants and maternal 
death as a result of frequent and severe malaria infections [48] .  
In malaria-endemic countries, pregnant women receive sulfadoxine-pyrimathamine 
(SP) intermittent preventive therapy (IPT) to prevent malaria and its complications [80]. The 
World Health Organization (WHO) currently recommends that HIV-infected pregnant women 
receiving daily trimethoprim-sulfamethoxazole (cotrimoxazole; CTX) prophylaxis should not 
be given SP-IPTp to avoid adverse drug reactions associated with sulphur toxicity [3]. 
Countries like Uganda and Malawi, currently recommend daily CTX to all HIV-infected 
pregnant women to prevent opportunistic infections [217]. However, these recommendations 
are not based on empirical evidence [242, 243]. Although CTX has been shown to decrease 
malaria morbidity in children and HIV-infected adults [70, 77-79], its efficacy, safety and 
effectiveness to prevent malaria have not been evaluated especially in HIV-infected 
pregnant women [216]. No [79] study has assessed the effects of daily CTX prophylaxis 
compared to SP-IPTp in HIV-infected pregnant women.  
We analyzed data from a cross-sectional study that was conducted to investigate the 
effects of iron supplementation on maternal morbidities. We compared the prevalence of 
malaria infection and anemia in HIV-infected pregnant women taking daily CTX with or 
without SP-IPTp to those taking SP-IPTp only.  
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Methods 
Study site 
The study was conducted from December 2005 to July 2009 in the antenatal clinic at Thyolo 
district hospital, in southern Malawi. The hospital provides free antenatal services and has a 
well established prevention of mother-to-child transmission of HIV (PMTCT) program. CD4 
T-cell count measurements and WHO HIV clinical staging are performed on all women 
found to be HIV-infected. HIV-infected pregnant women classified into WHO HIV Stage III or 
IV or those with CD4 count below 250 received combination anti-retroviral therapy (ART) 
containing stavudine (30-40mg), lamivudine (150mg) and nevirapine (200mg), twice daily as 
a fixed dose combination (Triomune) [244]. In line with WHO and Ministry of Health 
recommendations, in 2007, cotrimoxazole prophylaxis (480mg twice daily) for the prevention 
of opportunistic infections was introduced at the hospital [245]. However, confusion about 
the exact implementation of this policy resulted in some women receiving SP-IPTp only and 
others receiving a combination of daily CTX and SP-IPTp.  
Study population, enrolment and data collection 
We used data from a cross-sectional study investigating the effects of routine iron 
supplementation in HIV-infected pregnant women on maternal morbidities. The study 
enrolled HIV-infected pregnant women attending routine antenatal services at the hospital at 
least 15 years old and with gestation ≥34 weeks. Women with immediate life-threatening 
medical and obstetric conditions were excluded.  
Following enrolment, a standardized questionnaire was administered to collect data 
which included socio-demographic and medical information, intake of medications such as 
antiretroviral drugs, SP-IPT, CTX and iron supplements and the use of bed nets. Physical 
medical examination was also performed which included measurement of temperature, 
blood pressure, mid-upper arm circumference (MUAC), weight and height. Thereafter, 
peripheral venous blood was collected for thick blood smear malaria microscopy and later, 
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for malaria DNA detection using real-time polymerase chain reaction (PCR). The study was 
approved by the Malawi College of Medicine Research and Ethics Committee and by the 
institutional review board of the University of North Carolina at Chapel Hill. All women 
provided informed consent before enrolment. 
Laboratory tests 
Thick blood smears were stained with Field’s stains A and B light microscopy [102]. 
Using light microscopy, two independent laboratory technicians examined the stained 
smears to detect asexual forms of plasmodium falciparum malaria parasites. In case of 
discrepancy of results, an experienced microscopist re-read the slides, as a tie breaker. 
Malaria parasites were counted against 200 leukocytes. To estimate the parasite density per 
microlitre of blood, the number of parasites counted was multiplied by 40 under the 
assumption of leukocyte count of 8,000 per microlitre of blood. A blood film was considered 
negative if no parasites were detected per 200 leukocytes. 
To increase the detection of malaria infection, we also conducted real-time 
polymerase chain reaction (RT-PCR) for malaria parasite DNA at the University of North 
Carolina at Chapel Hill (UNC-CH). DNA was extracted from dried filter paper using an 
invitrogen PureLink Genomic DNA kit (Invitrogen, Carlsbad, USA) as per manufacturer’s 
instructions. PCR amplification of the malaria parasite DNA was done in two steps using a 
pooling method as described in [231]. CD4 T-cell count was performed using Partec CyFlow 
counter (Partec GmbH, Munster, Germany). Hemoglobin concentration (Hb) measurement 
was performed on whole blood using a Hemocue hemoglobinometer (HemoCue AB, 
Ängelholm, Sweden). 
Definitions 
Microscopic malaria infection was defined as presence of malaria parasites on 
microscopy; PCR-detected malaria infection was defined as positive malaria result by PCR 
regardless of microscopy results. Anemia was defined as hemoglobin concentration <11g/dl. 
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Women were classified into 4 groups of anti-malarial drug exposure based on reported 
information verified with antenatal records; 1) SP-IPTp plus CTX 2) CTX only 3) SP-IPTp 
only and 4) None (No SP-IPTp or CTX).  
Statistical analysis 
Data were analyzed using SAS software version 9.1 (SAS Institute Inc., Cary, NC, 
USA). In bivariate analyses, Analysis of variance (ANOVA) or student’s t-test were used 
were used to compare differences between or among outcomes or exposure and continuous 
variables that were normally distributed variables. Kruskal-Wallis test or Wilcoxon rank sum 
test were used for continuous variables that were not normally distributed variables. 
Pearson chi-square test was used for categorical variables.  
Effect measure modification (EMM) was evaluated using likelihood ratio test of the 
interaction term. Directed acyclic graphs (DAGs) were used to identify potential confounders 
for the association of anti-malarial drug exposure with malaria infection or maternal anemia 
[239, 240].  A backward elimination strategy was applied to select the best model using the 
absolute change in estimate criterion of at least 10%. Results from the initial full model were 
adopted and are presented since the effect estimates and their precision were not different 
between the final model (after confounder evaluation) and the initial full model. Variables 
that were assessed for confounding and EMM included; age (<27years or ≥27years), 
gravidity (primgavidae, secondigravidae and multigravidae), number of antenatal visits, CD4 
count (< 200, 200–499 and ≥ 500 cells/µL), body mass index (BMI) and socio-economic 
status (SES- poor, middle and high). SES was obtained by calculating the wealth index 
using the method as described in Gwatkin et al. [246, 247]. Since SP-IPTp has been the 
standard of care for malaria prevention during pregnancy, SP-IPTp group was used as a 
referent. 
Logistic regression was used in the analysis of the association between anti-malarial 
drug exposure and malaria infection. Log-binomial regression [235-237] and linear 
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regression were used in the analysis of the association of anti-malarial drug exposure with 
anemia and hemoglobin concentration respectively. Poisson regression model with robust 
variance estimator was performed to confirm estimates from log-binomial regression [235, 
238]. 
Results 
Study population 
From December 2005 to July 2009, 1,142 HIV-infected pregnant women were 
enrolled of whom 6.2% (71/1141) were primigravidae and 90.8% (1034/1139) were married. 
They had a median age (range) of 27 years (16-46 years) and median CD4 cell count 
(range) of 423 cells/µL (11-1528 cells/µL). Use of bed nets was reported in 59.6% 
(675/1133) of the women and 48.5% (554/1,142) of them reported taking antiretroviral 
drugs.  
Anti-malarial drug exposure 
Data on the use of SP-IPTp and CTX were available for 98.2% (1,121/1,142) of the 
enrolled women. Among these, 49.7% (557), 29.8% (334), and 15.4% (173) reported taking 
SP-IPTp only, CTX only and SP-IPTp plus CTX, respectively. Only 5.1% (57) reported 
taking none of the drugs. The groups were similar in terms of HIV disease clinical stage, 
CD4 count, socio-economic status and marital status (Table 4.1). However, women in the 
SP-IPTp only group were significantly younger, less likely to use bed nets, more likely to be 
primigravidae and, less likely to report taking ARV drugs compared to women in CTX or 
CTX plus SP-IPTp groups (Table 4.1).   
Prevalence of malaria infection and anemia 
Blood smear microscopy and RT-PCR results were available for 97.5% (1,114/1,142) 
and 98.8% (1,128/1,142) of women respectively. The prevalence of PCR-detected malaria 
infection was almost two times higher (10.0% [113/1,128]) than microscopic malaria (5.5% 
[61/1,114]). All PCR-positive malaria infections were due to P. falciparum among those that 
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had information on parasite species (n=70). However, 4.3% (3/70) had P. falciparum and P. 
malariae mixed infections while 1.4% (1/70) had P. falciparum and P. ovale. Data on 
hemoglobin concentration were available for 99.8% (1,140/1,142) of the women. The 
prevalence of anemia was 45.1% (514/1,140). 
Associations between CTX and/or SP-IPT and malaria infection 
The prevalence of microscopic and PCR-detected malaria infection was significantly 
lower in women reporting taking CTX plus SP-IPTp (0.6% and 3.6%) and CTX only (2.7% 
and 5.5%) than those reporting taking SP-IPTp only (7.7% and 13.5%) (Figure 4.1). The 
prevalence of microscopic malaria infection and PCR-detected malaria infection tended to 
be higher in women who reported not taking CTX or SP-IPT (14.0% and 19.6%) than those 
reporting taking SP-IPTp only, but the difference was not statistically significant (Table 4.2).  
After adjusting for age, gravidity, number of antenatal visits, CD4 cell count, bed net 
use and SES, the odds of microscopic malaria infection were significantly lower in women 
reporting taking CTX plus SP-IPTp (Adjusted OR, [95% CI]: 0.09, [0.01-0.66]) or CTX 
(Adjusted OR, [95% CI]: 0.43, [0.19-0.97] than in women who reported taking SP-IPTp only 
(Table 4.2).  Likewise, after adjusting for same variables above, the odds of  PCR-detected 
malaria infection were significantly lower in women who reported taking CTX plus SP-IPTp 
(Adjusted OR, [95% CI]: 0.24, [0.10-0.62]) or CTX only (adjusted OR, [95% CI]: 0.44, [0.25-
0.78]) than women who reported taking SP-IPTp only (Table 4.2). The odds of microscopic 
malaria infection were higher in women who reported not taking CTX or SP-IPTp compared 
to those who reported taking SP-IPTp only (Adjusted OR, [95% CI]: 1.84, [0.87-4.41]) but 
this was not statistically different (Table 4.2). The odds of microscopic malaria infection or 
PCR-detected malaria infection were not statistically different in women who reported taking 
CTX plus SP-IPTp compared to women who reported taking CTX only (Adjusted OR, [95% 
CI]: 0.21, [0.03-1.67] and 0.56, [0.20-1.56] respectively). We also observed that the 
prevalence of microscopic and PCR-detected malaria infection were lower in women who 
 56 
 
had taken CTX for ≥30 days than in women who took CTX for <30 days (1.2% and 4.0% 
versus 6.7% and 9.6% respectively).  
Associations of CTX and/or SP-IPT with anemia and hemoglobin concentration 
The prevalence of anemia was significantly lower in women who reported taking CTX 
plus SP-IPTp (34.7%) or CTX only (35.6%) than women who reported taking SP-IPTp only 
(52.4%) (Table 4.3). After adjusting for age, gravidity, number of antenatal visits, CD4 count 
and BMI, the prevalence of maternal anemia remained significantly lower in women who 
reported taking CTX plus SP-IPTp (Adjusted prevalence ratio (APR), [95% CI]: 0.67, [0.54-
0.83]  or CTX only (APR, [95% CI]: 0.72 [0.61-0.83]) than in women who reported taking SP-
IPTp only.  
Similarly, the mean Hb concentration was significantly higher in women who reported 
taking CTX plus SP-IPTp (Mean Hb [standard deviation]: 11.4g/dl [1.33]; p<0.0001) or CTX 
only (Mean Hb [SD]: 11.4 [1.36]; p<0.0001) than in women who reported taking SP-IPTp 
only (Mean Hb [SD]: 10.8g/dl [1.35]) (Table 4.3).  After adjusting for age, gravidity, number 
of antenatal visits, CD4 count and BMI, the mean Hb remained significantly higher in women 
who reported taking CTX plus SP-IPTp (Adjusted difference in Hb means, [95% CI]: 0.52, 
[0.29, 0.75]) or CTX only (Adjusted difference in Hb means, [95% CI]: 0.46 [0.27, 0.64]). 
Compared to women who took CTX for >60 days, women who took CTX for <30 days had 
lower Hb concentration (Adjusted difference in Hb means, [95%CI]: -0.44, [-0.80,-0.07]; 
p=0.02) (Table 4.3). We found no significant association between duration of CTX intake 
and the prevalence of anemia (Table 4.3). 
Discussion 
This study was conducted in a SSA setting where approximately 1 in 5 of pregnant 
women attending antenatal clinics is HIV-infected [248]. During the first years of the study 
the Malawi national policy for prevention of malaria in HIV-infected pregnant women was the 
use of at least 3 doses of SP-IPTp and insecticide-treated bednets (ITNs). Subsequently, 
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the policy changed to the use of daily CTX and ITNs in those with CD4 counts <500 or in 
WHO HIV clinical stages II, III and IV. Women who were on daily CTX prophylaxis were not 
supposed to receive SP-IPT [245]. However, during the period of transition to this new 
policy, some women received both SP-IPTp and CTX.  
Our study found that, after adjusting for important confounders, CTX with or without 
SP-IPTp was associated with reduced prevalence of both microscopic and PCR-detected 
malaria infections and anemia compared to SP-IPTp alone in HIV-infected pregnant women. 
To our knowledge, this is the first report demonstrating the superior effectiveness of CTX 
against malaria compared to SP-IPTp in HIV-infected pregnant women. Our findings are 
similar to studies demonstrating the effectiveness of CTX in reducing malaria in children and 
HIV-infected adults [70, 78, 79]. However, a recent Ugandan study found no difference in 
the prevalence of placental malaria between HIV-infected pregnant who took CTX and HIV-
uninfected pregnant women who took SP-IPTp [217]. This result is difficult to compare with 
our findings because HIV-infected and uninfected pregnant women used different drugs. 
Nevertheless, it is known that malaria infection is more frequent and SP-IPT is less 
efficacious in HIV-infected than HIV-uninfected pregnant women [53-56]. The fact that, in 
the Ugandan study, CTX reduced the risk of malaria in HIV-infected pregnant women to a 
level similar to SP-IPT in HIV-uninfected women indirectly suggests the superior efficacy of 
CTX in preventing malaria in HIV-infected pregnant women.  
The anti-malarial effects of CTX and SP depend on their ability to inhibit parasite 
DHFR and DHPS, thereby blocking parasite folate synthesis. The setting where this study 
was conducted has a high prevalence of triple Asn-108/Ile-51/Arg-59 DHFR and double Gly-
437/Glu-540 DHPS mutations which reduce the efficacy of these drugs and has rendered 
SP ineffective in under five children [249]. So why was CTX more effective than SP?  First, 
this could be due to frequent dosing of CTX to the pregnant women compared with SP. CTX 
prophylaxis was taken daily which may have resulted in higher average anti-malarial blood 
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levels compared with two or three doses intermittent SP doses taken during pregnancy. This 
explanation is partly supported by our observation of lower prevalence of malaria infection in 
women who took daily CTX for a longer duration and in those who took CTX plus SP than 
CTX only. Indeed, some investigators have even suggested increasing the number of SP 
doses in HIV-infected pregnant women not on daily CTX [250]. In pregnant women, three 
tablets of SP given intermittently may not achieve adequate blood levels to prevent or clear 
malaria infection because of increased blood elimination of sulphadoxine and 
pyrimethamine [251]. Second, based on in vitro studies, it is possible that there is 
incomplete cross resistance to pyrimethamine and trimethroprim [252] although other 
studies have found complete cross resistance [253]. In vivo, some parasites resistant to 
pyrimethamine have been shown to be sensitive to trimethroprim [254].  
Since CTX and SP are anti-folates, intake of both drugs may increase the risk of 
anemia due to inhibition of folate synthesis [255]. CTX intake during pregnancy has been 
shown to increase the risk of folate deficiency leading to maternal anemia and poor birth 
outcomes [256-259] including neural birth defects [260-262]. However, we found that CTX 
with or without SP-IPTp was associated with reduced prevalence of maternal anemia and 
higher hemoglobin concentration.  
Our study had several limitations. First, because participants were not randomized to 
anti-malarial drug groups, there is potential for residual confounding by unmeasured factors. 
Because of the cross-sectional design of our study, with only one point measurement of 
both the outcomes and exposure, no causal inferences can be made from our findings. 
Second, our study may have underestimated the true impact of CTX with or without SP-IPTp 
on malaria infection or anemia because participants were only enrolled in third trimester of 
pregnancy. The study may have missed some malaria infections that occurred in the first or 
second trimester during which pregnant women are at an increased risk of malaria infection 
[263]. Third, there is potential that our results may 
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since anti-malaria drug exposure was self-reported. Although antenatal records were used 
to verify prescription of medications, it was not possible to confirm compliance of drug 
intake, no drug levels were measured. Fourth, it may be argued that our data was 
confounded by the fact that the reduced risk of malaria infection may have coincided with 
the policy change from SP-IPTp to CTX. This seems less likely because adjusting for 
season of enrolment did not significantly change our results. Finally, our study did not 
evaluate the effects of CTX intake with or without SP-IPTp in different trimesters. This could 
have allowed better assessment of effects of CTX on fetal and maternal toxicity. 
Furthermore, our data were collected during the antenatal period only and did not follow 
women up to delivery to assess the effects of CTX on birth outcomes. 
Our study also demonstrated the challenges that resource-limited countries like 
Malawi encounter when changing drug policies. In our retrospective study, some women 
received anti-malarial drug regimens that were inconsistent with the newly introduced drug 
policy. This was common in settings where disease-specific programs such as HIV care 
services were not well into the maternal health programs. This resulted in poor information 
exchange among staff providing care to the same client. CTX prophylaxis drug policy to 
prevent opportunistic infections was not adequately shared with or understood by antenatal 
clinic staff providing antenatal services. This experience shows that to effectively introduce a 
public health policy, proper planning and timely training of health personnel should always 
precede implementation especially in settings where frequent policy changes do take place. 
In conclusion, our study provides the evidence that daily CTX is more effective at reducing 
malaria infections and anemia compared to SP-IPTp in HIV-infected pregnant women. 
Evidence from our study supports the use of daily CTX in preventing malaria in HIV-infected 
pregnant women instead of SP-IPTp.  However, a longitudinal study is required to assess 
the toxic effects of daily CTX on pregnancy outcomes such as birth defects.   
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Table 4.1: Characteristics of HIV-infected pregnant women according to SP-IPTp and CTX 
intake during pregnancy attending Thyolo district Hospital antenatal clinic (2005-2009) 
Characteristic 
Drug group 
SP & CTX 
(n=173) 
CTX  only 
(n=334) 
SP only  
(n=557) 
None (n= 57) p-value 
 
Age in years , median (range) 
 
28 (18-40) 
 
27 (16-46) 
 
26 (16-45) 
 
27 (16-37) 
 
<0.0001 
 
Gravidity : Median (range) 
Primigravidae (%) 
Secundigravidae (%) 
 
4 (1-9) 
8 (4.6) 
25 (14.5) 
 
4 (1-9) 
16 (4.8) 
42 (12.6) 
 
3 (1-11) 
44 (7.9) 
112 (20.1) 
 
3 (1-7) 
2 (3.5) 
20 (35.1) 
0.002 
0.0001 
 
ANC visits: Median (range) 
< 3 visits (%) 
≥3 visits (%) 
 
3 (1-5) 
40 (23.1) 
133 (76.9) 
 
3 (1-8) 
116 (34.8) 
217 (65.2) 
 
3 (1-8) 
236 (42.4) 
321 (57.6) 
 
2 (1-4) 
44 (77.2) 
13 (22.8) 
 
0.0001 
<0.0001 
Any Bed-net use* 
Yes 
 
110 (63.6) 
 
264 (79.5) 
 
271 (49.2) 
 
24 (42.1) 
 
0.001 
CD4  cell count (cells/μl): 
 Mean (SD) 
<200 (%) 
200-499 (%) 
≥ 500 (%) 
 
423 (213.3) 
 
19 (11.0) 
100 (57.8) 
54 (31.2) 
 
477.6 (291.6) 
 
25 (7.5) 
170 (50.9) 
139 (41.6) 
 
446.0 (229.9) 
 
65 (11.7) 
296 (53.1) 
196 (35.2) 
 
477.1 (203.2) 
 
5 (8.8) 
24 (42.1) 
28 (49.1) 
 
0.04 
 
0.05 
 
WHO HIV clinical stage 
I or II 
III or IV 
 
 
142 (83.0) 
29 (17.0) 
 
 
298 (89.8) 
34 (10.2) 
 
 
487 (87.4) 
70 (12.6) 
 
 
52 (92.9) 
4 (7.1) 
 
 
0.10 
Antiretroviral drug use (%) 
Yes 
 
142 (82.1) 
 
277 (82.9) 
 
128 (23.0) 
 
4 (7.0) 
 
0.0001 
 
Body Mass Index : mean(SD)** 
 
23.6 (2.5) 
 
23.7 (2.6) 
 
23.2 (2.4) 
 
 
23.4 (2.3) 
 
0.04 
 
MUAC :Median (range)¥ 
  
25.4 (20.0-33.0) 
 
25.2 (20.0-35.0) 
 
24.1 (18.0-36.8) 
 
24.4 (20.6-30.8) 
 
0.001 
 
Socio-economic status (%) 
Poor 
Middle 
High 
 
 
59 (35.1) 
69 (41.1) 
40 (23.8) 
 
 
127 (38.5) 
120 (36.4) 
83 (25.2) 
 
 
230 (41.6) 
203 (36.7) 
120 (21.7) 
 
 
27 (48.2) 
19 (33.9) 
10 (17.9) 
 
 
0.52 
 
Married (%) † 
 
157 (90.8) 
 
302 (90.4) 
 
510 (91.7) 
 
47 (82.5) 
 
0.14 
*Bed net use missing in groups: CTX:n=2; SP-IPTp:n=6 
**BMI missing in groups: CTX:n=2;SP-IPTp:n=2 
¥MUAC  missing in groups: CTX&SP-IPTp: n=1; CTX: n=20; SP-IPTp :n=2; None:n=1 
†Marital status missing in group:None:n=1 
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Table 4.2: Factors associated with malaria infection among HIV-infected pregnant women from Thyolo district Hospital antenatal 
clinic in Malawi (2005-2009) 
Characteristic 
Microscopic infection PCR-detected infection 
n(% infected) Crude OR (95% CI) Adjusted OR (95%CI)¥ n(% infected) Crude OR (95% CI) Adjusted OR (95%CI)¥ 
Anti-malarial drug 
None 
SP-IPTp 
Cotrimoxazole 
SP-IPTp & Cotrimoxazole 
 
57 (14.0) 
532 (7.7) 
333 (2.7) 
171 (0.6) 
 
1.96 (0.87-4.41) 
1.00 
0.33 (0.16-0.69) 
0.07 (0.01-0.52) 
 
1.84 (0.76-4.46) 
1.00 
0.43 (0.19-0.98) 
0.09 (0.01-0.66) 
 
56 (19.6) 
554 (13.5) 
329 (5.5) 
168 (3.6) 
 
1.56 (0.77-3.15) 
1.00 
0.37 (0.22-0.63) 
0.24 (0.10-0.55) 
 
1.39 (0.66-2.94) 
1.00 
0.44 (0.25-0.78) 
0.24 (0.10-0.62) 
Age in years  
≥ 27 
<27 
 
584 (4.1) 
529 (7.0) 
 
1.00 
1.76 (1.04-2.98) 
 
1.00 
1.27 (0.68-2.38) 
 
593 (8.1) 
536 (11.9) 
 
1.00 
1.54 (1.04-2.28) 
 
1.00 
1.16 (0.73-1.85) 
Gravidity (%) 
Multigravidae 
Secundigravidae 
Primgravidae 
 
849 (4.7) 
194 (8.8) 
70 (5.7) 
 
1.00 
1.94 (1.08-3.51) 
1.23 (0.43-3.53) 
 
1.00 
1.75 (0.88-3.46) 
1.12 (0.36-3.52) 
 
861 (8.6) 
198 (13.6) 
70 (15.7) 
 
1.00 
1.68 (1.05-2.69) 
1.98 (1.00-3.93) 
 
1.00 
1.58 (0.93-2.71) 
2.00 (0.93-4.29) 
ANC visits: (%) 
≤ 3 
>3 
 
667 (5.0) 
445 (6.3) 
 
1.00 
1.29 (0.77-2.17) 
 
1.00 
0.85 (0.48-1.53) 
 
675 (8.3) 
451 (12.4) 
 
1.00 
1.57 (1.06-2.31) 
 
1.00 
1.20 (0.78-1.84) 
Any Bed-net use 
Yes 
No 
 
662 (3.02) 
443 (8.6) 
 
1.00 
3.01 (1.73-5.25) 
 
1.00 
2.11 (1.16-3.83) 
 
665 (7.4) 
454 (13.2) 
 
1.00 
1.91 (1.29-2.85) 
 
1.00 
1.31 (0.85-2.02) 
CD4 T cell count (cells/μl): 
≥ 500 
200-499 
<200 
 
416 (5.8) 
581 (5.3) 
117 (5.1) 
 
1.00 
0.92 (0.53-1.59) 
0.88 (0.35-2.21) 
 
1.00 
1.00 (0.55-1.81) 
1.08 (0.41-2.82) 
 
419 (10.3) 
591 (10.3) 
118 (7.6) 
 
1.00 
1.01 (0.67-1.52) 
0.72 (0.34-1.53) 
 
1.00 
1.01 (0.65-1.57) 
0.82 (0.38-1.77) 
WHO HIV clinical stage 
III or IV 
I or II 
 
134 (1.5) 
975 (6.0) 
 
1.00 
4.17 (1.00-17.29) 
- 
 
138 (6.5) 
985 (10.5) 
 
1.00 
1.67 (0.83-3.39) 
 
- 
 
Antiretroviral drug use (%) 
Yes 
No 
 
546 (2.0) 
568 (8.8) 
 
1.00 
4.70 (2.42-9.12) 
- 
 
546 (5.3) 
582 (14.4) 
 
1.00 
3.01 (1.94-4.67) 
- 
Season of enrolment 
Dry 
Rainy 
 
607 (4.0) 
505 (7.3) 
 
1.00 
1.92 (1.13-3.26) 
 
- 
 
613 (6.2) 
513 (14.2) 
 
1.00 
2.55 (1.69-3.85) 
- 
¥ Adjusted for age, gravidity, number of antenatal visits, bed net use, CD4 cell count and socio-economic status  
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Table 4.2 continued 
 
 
 
 
 
 
 
Table 4.3: Maternal anemia (Hb<11g/dl) and hemoglobin concentration (Hb) by anti-malaria drug group in HIV-infected pregnant 
women at Thyolo district Hospital, Malawi (2005-2009) 
 
 
 
 
 
Characteristic Microscopic infection PCR-detected infection 
n(% infected) Crude OR (95% CI) Adjusted OR (95%CI)¥ n(% infected) Crude OR (95% CI) Adjusted OR (95%CI)¥ 
BMI (%) 
>24.9 
18.5-24.9 
< 18.5 
 
277 (4.7) 
817 (5.9) 
16 (0.0) 
 
1.00 
1.27 (0.68-2.38) 
- 
- 
 
277 (7.6) 
831 (10.9) 
16 (6.2) 
 
1.00 
1.50 (0.91-2.46) 
0.81 (0.10-6.46) 
 
- 
Socio-economic status (%) 
High 
Middle 
Poor 
 
248 (2.4) 
409 (6.1) 
442 (6.8) 
 
1.00 
2.63 (1.06-6.49) 
2.94 (1.21-7.15) 
 
1.00 
2.10 (0.82-5.35) 
2.51 (1.00-6.30) 
 
247 (6.1) 
419 (9.6) 
448 (12.3) 
 
1.00 
1.63 (0.88-3.02) 
2.17 (1.20-3.92) 
 
1.00 
2.16 (1.16-4.00) 
1.50 (0.79-2.83) 
¥ Adjusted for age, gravidity, number of antenatal visits, bed net use, CD4 cell count and socio-economic status  
Group 
Hb concentration Anemia 
n Mean Hb  
(SD)* 
Difference in Hb 
means (95% CI)§ 
p-value %  PR (95% CI)§ p-value 
Anti-malarial drug  
None 
SP-IPTp 
Cotrimoxazole 
SP-IPTp & Cotrimoxazole  
 
57 
557 
334 
173 
 
10.64 (1.32) 
10.86 (1.35) 
11.37 (1.36)a 
11.39 (1.33)b 
 
-0.27 (-0.64,0.09) 
Ref 
0.46 (0.27,0.64) 
0.52 (0.29, 0.75) 
 
0.14 
Ref 
<0.0001 
<0.0001 
 
61.4 
52.4 
35.6 
34.7 
 
1.21 (0.99-1.48) 
Ref 
0.72 (0.61-0.83) 
0.67 (0.54-0.83) 
 
0.06 
Ref 
0.0001 
0.0003 
Duration of cotrimoxazole 
<30 days 
30-60 days 
>60 days 
 
77 
124 
282 
 
11.08 (1.11) 
11.24 (1.29) 
11.49 (1.44) 
 
-0.44 (-0.80,-0.07) 
-0.25 (-0.55,0.05) 
Ref. 
 
0.02 
0.11 
Ref 
 
42.9 
36.3 
34.8 
 
1.31 (0.97-1.77) 
1.05 (0.79-1.40) 
Ref 
 
0.08 
0.73 
Ref 
*Analysis of variance test for the means: anti-malarial drug p=<0.0001;  duration of cotrimoxazole p=0.04 
§ Adjusted for age, gravidity, number of antenatal visits, CD4 count and body mass index 
a= Student’s t-test between Cotrimoxazole and SP-IPTp groups; p<0.0001 
b= Student’s t-test between Cotrimoxazole plus SP-IPTp and SP-IPTp groups; p<0.0001 
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Figure 4.1: Prevalence of malaria with 95% CI by anti-malarial drug intake in HIV-infected 
pregnant women at Thyolo district hospital, Malawi (2005-2009) 
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER 5: ASSOCIATION BETWEEN SUBMICROSCOPIC MALARIA INFECTION 
AND MATERNAL ANEMIA IN HIV-INFECTED PREGNANT WOMEN IN MALAWI 
 
ABSTRACT 
Background: The risk factors and effects of submicroscopic malaria infections, i.e. parasite 
DNA is detected in blood but parasites are not seen on microscopy, in pregnancy are 
unclear and have not been studied in HIV-infected pregnant women. We investigated the 
predictors and effect of submicroscopic malaria infection on maternal anemia and 
hemoglobin concentration in HIV-infected pregnant women. 
Methods: From December 2005 to July 2009, 1,142 HIV-infected pregnant women 
attending Thyolo district hospital antenatal clinic were recruited in a cross-sectional study. 
Peripheral blood was tested for hemoglobin concentration (Hb) and malaria infection using 
light microscopy and real-time-PCR (RT-PCR). Information on socio-demographics, 
obstetric and medical history, use of malaria control interventions during pregnancy was 
collected using a standardized questionnaire and antenatal records.  
Findings: Information on both light microscopy and RT-PCR was available for 96.4% 
(1,101/1,142) of the women. The prevalence of submicroscopic malaria infections was 4.5% 
(. The prevalence of maternal anemia was higher in women with submicroscopic malaria 
infection (APR =1.44; 95%CI 1.18-1.76) compared to women without malaria infection. The 
mean Hb concentration of women with submicroscopic malaria infection was lower 
compared to women with no malaria infection (Adjusted mean difference=-0.69; 95% CI -
1.03,-0.35; p=<0.0001). The prevalence of submicroscopic malaria infection was higher in 
primigravidae compared to multigravidae (Adjusted prevalence ratio (APR) [95%CI]: 2.72 
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[1.13-6.53]), higher in rainy season (APR: 3.04 [1.63-5.67]), and higher in women not taking 
cotrimoxazole (APR: 2.00 [1.06-3.73]).  
Conclusion: Submicroscopic malaria infection in HIV-infected pregnant women increases 
the risk of maternal anemia and reduces hemoglobin concentration. The effects of 
submicroscopic malaria infection on fetal outcomes in this population need to be studied. 
Introduction 
Malaria infections during pregnancy are associated with maternal anemia, abortion, 
preterm delivery and low birth weight (LBW) [2, 6, 13] and these are risk factors for maternal 
and neonatal mortality. In malaria-endemic areas, a large number of pregnant women 
harbor submicroscopic malaria infections i.e parasite DNA is detected in their blood but 
parasites are not seen on microscopic examination [24, 41, 61-64]. In high and stable 
malaria transmission areas, adults acquire malaria immunity after repeated malaria 
infections during childhood [73, 264][73]. Findings from studies on submicroscopic malaria 
infection in children and adults suggest that submicroscopic malaria infections have an 
important role in the acquisition of natural malaria immunity [265, 266]. This acquired 
malaria immunity prevents the severe clinical manifestations of malaria infections and 
reduces parasite loads but does not prevent infection. Pregnant women infected with 
malaria parasites in high transmission areas are semi-immune, usually asymptomatic [5] 
and may only present with severe anemia as a result of frequent infections [6]. 
Little is known about factors that influence the occurrence of submicroscopic malaria 
infection [65] and the clinical importance of submicroscopic malaria in pregnant women is 
unclear. While some studies in pregnant women of unknown HIV status have found an 
association between submicroscopic malaria infections and maternal anemia or LBW [41, 
72, 73], others have not [24, 61, 62, 218]. Although submicroscopic malaria infection has 
been studied in pregnant women of unknown HIV status, risk factors and effects of 
submicroscopic malaria in HIV-infected pregnant women are not known. HIV infection 
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impairs the immune response against malaria infection and compromises the acquired anti-
malarial immunity [51, 52, 219, 220] and submicroscopic malaria infection may be of clinical 
significance in HIV-infected pregnant women.  
We examined the association between submicroscopic malaria infection and maternal 
anemia and hemoglobin concentration in HIV-infected pregnant women attending the 
antenatal clinic at Thyolo district hospital in Malawi. The study also assessed predictors of 
submicroscopic malaria infections in this population. 
Methods 
Study site 
The study was done at Thyolo district hospital in rural Malawi. The district covers an 
area of 1,715 km² with an estimated total population of 587,455 of whom 52% are females 
[228]. The hospital provides free antenatal services and has a well established prevention of 
mother-to-child transmission of HIV (PMTCT) program. All HIV-infected pregnant women 
classified into WHO HIV Stage III or IV or those with CD4 count below 250 receive 
combination Anti-Retroviral Therapy (ART) containing stavudine, lamivudine and nevirapine 
(Triomune) [244]. HIV-infected pregnant women in HIV disease clinical stage II to IV or with 
CD4 count <500 received daily cotrimoxazole (CTX) prophylaxis for prevention of 
opportunistic infections.  
Study population and recruitment 
HIV-infected pregnant women with gestation ≥34 weeks attending routine antenatal 
services in third trimester at the hospital were enrolled between December 2005 and July 
2009. Women <15 years and those with immediate life-threatening medical and obstetric 
conditions were excluded. Socio-demographic and medical information was obtained using 
a standardized questionnaire. Physical medical examination which included measurement of 
temperature, blood pressure, MUAC, weight and height was performed. The study was 
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approved by the Malawi College of Medicine Research and Ethics Committee and by the 
institutional review board of the University of North Carolina at Chapel Hill. 
Laboratory tests 
The procedures have been described in detail in section 3.1.3 above. Briefly, malaria 
was detected by light microscopy of thick blood smears using Field’s stains A and B as 
described in [[102]].  Real-time-Polymerase chain reaction (RT-PCR) tests for malaria 
parasite DNA were also conducted. DNA was extracted using an invitrogen PureLink 
Genomic DNA kit (Invitrogen, Carlsbad, USA) as per manufacturer’s instructions. PCR 
amplification of the malaria parasite DNA was done in two steps using a pooling method as 
described in [231]. CD4 count was performed using the FACS count flow cytometer (Becton-
Dickinson, San Jose, CA). Hemoglobin concentration (Hb) measurement was performed on 
whole blood using a Hemocue hemoglobinometer (HemoCue AB, Ängelholm, Sweden). 
Definitions 
Malaria infection exposure was classified in 3 groups; microscopic, submicroscopic, 
or no malaria. Microscopic malaria infection was defined as a positive microscopy. 
Submicroscopic malaria infection was defined as a RT-PCR positive result with a negative 
microscopy result. No malaria was defined as negative result by both method. Anemia was 
defined as Hb <11g/dl. 
Statistical analyses 
Data were analyzed using SAS software version 9.1 (SAS Institute Inc., Cary, NC, 
USA). In bivariate analyses, Pearson chi-square test, analysis of variance (ANOVA) or 
student’s t-test and Kruskal-Wallis test or Wilcoxon rank sum test were used to compare 
between outcomes or exposure and categorical variables, normally distributed variables and 
non-normally distributed variables respectively.   
Effect measure modification was evaluated using likelihood ratio test of the 
interaction term between exposure and covariate in simple log-binomial regression model. 
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Directed acyclic graph (DAG) was used to identify potential confounders for the association 
between malaria infection and maternal anemia [239].Backward elimination strategy was 
applied to select the best model using the absolute change in estimate criterion as 
described in section 3.2.4.4 above. Potential confounders included; age (<27years or 
≥27years), gravidity (primigavidae, secondigravidae and Multigravidae), CD4 cell count (< 
200, 200–499 and ≥ 500 cells/µL), body mass index (BMI), Bed net use (Yes/No), season 
(Dry and rainy), CTX prophylaxis, and socio-economic status (SES-(poor, middle and high)). 
SES was obtained by calculating the wealth index using the method as described in [[246, 
247, 267]]. Education, employment status, housing building materials, household sanitation 
and water sources were used in calculating the household wealth index in our study. Only 
CTX intake was a strong confounder for the association between submicroscopic malaria 
and anemia. However, the estimates of the initial full model are presented since they were 
not different from the final reduced model.  
Logistic regression model was used in the assessment of predictors of submicroscopic 
malaria infection. In this analysis, malaria infection was analyzed as a binary variable 
(submicroscopic malaria infection/ no malaria). Log-binomial regression model [235-237] 
and linear regression model was used in the analysis of the association of malaria infection 
with maternal anemia and hemoglobin concentration respectively. Poisson regression model 
with robust variance estimator was performed to confirm estimates from log-binomial 
regression [235, 238]. 
Results 
Study population  
Of the 1,142 HIV-infected pregnant women enrolled, 96.4% (1,101/1,142) had results 
for both light microscopy and RT-PCR. 99.8% (1,140/1,142) had information on hemoglobin 
concentration. The median age was 27 years (range: 16-46 years) and 6.3% (69/1,100) 
were primigravidae.  Bed net use was reported in 59.8% (653/1,092) of the women and 
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45.1% (497/1,101) and 48.9% (538/1,101) of the women reported taking cotrimoxazole and 
ARVs during pregnancy respectively. The mean (standard deviation) of CD4 count, BMI and 
MUAC were 453.6 cells/µL (224.9), 23.4 kg/m2 (2.5) and 24.9 cm (2.0) respectively. 
Prevalence of malaria and anemia 
The prevalence of submicroscopic and microscopic malaria infections were 4.5% 
(50/1,101) and 5.5% (61/1,101) respectively. Compared to PCR, light microscopy had a 
sensitivity, specificity, positive predictive value and negative predictive value of 53.4%, 
99.2%, 90.4% and 93.7% respectively. Among those who were tested for plasmodium 
species, 4.3% (3/70) had P. falciparum and P. malariae mixed infections while 1.4% (1/70) 
had P. falciparum and P. ovale.  The prevalence of anemia was 45.1% (514/1,140). The 
prevalence of mild (9-10.9g/dl), moderate (7-8.9g/dl) and severe anemia (<7g/dl) was 
38.9%, 5.6% and 0.5% respectively. 
Predictors of submicroscopic malaria infection 
In multivariate analysis, the prevalence of submicroscopic malaria infection was 
higher in primigravidae compared to multigravidae (Adjusted prevalence ratio (APR) = 3.04; 
95% CI 1.63-5.67), higher in rainy season (APR = 3.04; 95% CI 1.63-5.67), and higher in 
women not taking CTX (APR= 2.00; 95%CI 1.06-3.73), Table 5.1. There was a significant 
trend of decreasing submicroscopic malaria infection with increasing gravidity (Mantel-
Haenzel chi-square test p=0.01).  
Characteristics of study participants by malaria infection  
The distributions of CD4 cell count, HIV disease clinical stage, socio-economic status 
and SP-IPTp use were not different across the malaria infection groups (Table 5.2). 
Compared to women without malaria infection, women that had submicroscopic malaria 
infection were more likely to be primigravid, be recruited in rainy season and less likely to 
report taking ARVs or CTX (Table 5.2). Compared to women who had microscopic malaria 
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infection, women with submicroscopic malaria were more likely to use bed nets (14.2% vs. 
5.9%, p=0.01), to take ARVs (36.0% vs. 18%, p=0.03) or CTX (30.0% vs. 16.4%, p=0.09).  
Association between submicroscopic malaria and anemia 
The prevalence of maternal anemia was higher in women with submicroscopic 
malaria infection (Prevalence Ratio (PR) = 1.59:95%CI 1.30-1.95) or microscopic infection 
(PR=1.46: 95%CI 1.19-1.80) compared to women without malaria infection. After adjusting 
for age, gravidity, bed net use, CTX prophylaxis, CD4 count, season of enrolment, BMI and 
socio-economic status, the prevalence of anemia was higher in women with submicroscopic 
malaria infection (Adjusted PR = 1.44:95%CI 1.17-1.78) or microscopic infection (APR=1.34: 
95%CI 1.10-1.63) than in women without malaria infection (Table 5.3). Other factors 
significantly associated with maternal anemia were CTX prophylaxis, CD4 count and BMI 
(Table 5.3).  
Submicroscopic malaria and hemoglobin concentration 
The mean Hb concentrations were lower in women with microscopic malaria infection 
(Adjusted Mean difference (AMD) =-0.71; 95%CI -1.08,-0.34; p<0.0001) or submicroscopic 
malaria infection (AMD=-0.69; 95% CI -1.03,-0.35; p<0.0001) compared to the mean Hb of 
women with no malaria infection adjusting for CTX intake and CD4 cell count (Table 5.4).  
Discussion 
We assessed the association between submicroscopic malaria infection and maternal 
anemia and investigated predictors associated with submicroscopic malaria infection in HIV-
infected pregnant women. The prevalence of maternal anemia was higher in women with 
submicroscopic malaria infection compared to women without malaria infection. The 
prevalence of submicroscopic malaria infection was higher in primigravid women, in women 
not taking cotrimoxazole and during rainy season. Compared to women who had 
microscopic malaria infection, women with submicroscopic malaria were more likely to use 
bed nets, to take ARVs or CTX.  
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Some drugs for the treatment of HIV and HIV-related diseases such as ARVs and 
CTX have been shown to have some anti-malarial effects [68-71] with potential to clear or 
reduce the density of malaria parasites. Studies have also shown that HIV-infected pregnant 
women use more antimalarial drugs than HIV-negative pregnant women [48]. First, 
treatment of all fevers as malaria in HIV-infected patients living in malaria-endemic areas 
has caused increased and unnecessary intake of antimalarial drugs, only 15% of fever 
reporters had malaria parasitemia in Malawian adults [67]. Second, WHO recommends 
more drug doses for intermittent preventive treatment of malaria in HIV-infected pregnant 
women compared to HIV-uninfected pregnant women [3]. We found that compared to 
women who had microscopic malaria, those with submicroscopic malaria infection were 
more likely to report taking ARVs or CTX. Also, the prevalence of ARVs or CTX intake was 
higher among women without malaria compared to women who had submicroscopic 
malaria. This suggests that the intake of ARVs and CTX probably cleared and reduced the 
density of malaria parasites to levels not detected by microscopy.  
Some studies have found submicroscopic malaria infections to be low throughout the 
year [62], common during dry season and not to be associated with seasonality [266]. 
However, we found submicroscopic malaria infections to be more prevalent during rainy 
season. In our study, bed net use was higher among women with no malaria infection or 
submicroscopic infection compared to women who had microscopic. Studies have 
consistently found that bed net use in malaria-endemic areas is higher during rainy season. 
It is possible that the use of bed nets especially during the rainy season reduced the 
frequency of mosquito bites and parasite inoculation rates in our study population.  
Previous studies among pregnant women of unknown HIV status have found 
submicroscopic malaria infection to be higher among multigravid women compared to 
primigravid women [41, 61]. It has been suggested that acquired immunity to malaria 
reduces the density of malaria parasites to low grade levels not detectable by microscopy 
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[66]. Indeed, studies in women of unknown HIV status have shown that malaria antibody 
levels are reduced in primigravid women compared to multigravid women [268]. However, in 
our study, we found that the prevalence of submicroscopic malaria infection decreased with 
increasing gravidity.  
Malaria infections in pregnancy causes maternal anemia through hemolysis of infected 
and un-infected red blood cells, specific or nonspecific immune responses that reduce red 
cell survival, defective red cell production, and hypersplenism [reviewed in [269]].  We found 
that HIV-infected pregnant women that had submicroscopic malaria or microscopic malaria 
had lower hemoglobin concentration and higher prevalence of anemia compared to women 
with no malaria infection. This suggests that submicroscopic malaria infection is of clinical 
significance in HIV-infected pregnant women. 
Our study had limitations. First, the cross-sectional design allowed only one point 
measurement of both the outcome and malaria infection in the third trimester, hence, no 
causal inferences can be made. Since data was only collected in the antenatal period, it was 
not possible to assess the effects of submicroscopic malaria on other clinically relevant 
pregnancy outcomes such as birth weight. Second, our study could have missed some 
malaria infections that occurred in the first or second trimester during which pregnant 
women are at an increased risk of malaria infection [263] and this may have an impacted 
our results.  
Our findings show availability and accessibility of effective malaria treatment and 
prevention strategies can reduce the malaria infections and associated complications in 
HIV-infected pregnant women. Making bed nets and effective drugs with anti-malarial effects 
like CTX or ARVs more available and accessible to HIV-infected pregnant women could 
reduce both microscopic and submicroscopic malaria infections and their complications in 
this high population.[79]  
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In conclusion, our data suggest that submicroscopic malaria infection in HIV-infected 
pregnant women is associated with seasonality, daily CTX prophylaxis and gravidity. 
Submicroscopic malaria infection increases the risk of maternal anemia in HIV-infected 
pregnant women. More effort should be exerted to make effective strategies more available 
and accessible to HIV-infected pregnant women to reduce malaria infections and its 
complications in this high risk population. Also, more research is needed to study the 
mechanisms and effects of submicroscopic malaria infection on birth weight in HIV-infected 
pregnant women. 
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Table 5.1: Factors associated with submicroscopic malaria infection in HIV-infected 
pregnant women attending Thyolo district Hospital antenatal clinic in Malawi (2005-2009) 
 
Characteristic n(% infected) Crude OR (95% CI) Adjusted OR (95%CI)** 
Age in years  
≥ 27 
<27 
 
552 (4.0) 
487 (5.5) 
 
1.00 
1.41 (0.79-2.52) 
- 
Gravidity (%) 
Multigravidae 
Secundigravidae 
Primigravidae 
 
800 (4.0) 
174 (5.6) 
65 (10.8) 
 
1.00 
1.46 (0.71-3.04) 
2.90 (1.23-6.85) 
 
1.00 
1.35 (0.64-2.82) 
2.72 (1.13-6.53) 
Any Bed-net use 
Yes 
No 
 
633 (4.6) 
401 (5.0) 
 
1.00 
1.09 (0.61-1.96) 
- 
 
SP-IPTp 
Yes 
No 
 
654 (5.5) 
367 (3.5) 
 
1.0 
0.63 (0.33-1.21) 
- 
Cotrimoxazole use 
Yes 
No 
 
487 (3.1) 
553 (6.3) 
 
1.0 
2.13 (1.15-3.94) 
 
1.0 
2.00 (1.06-3.73) 
Antiretroviral drug use (%) 
Yes 
No 
 
527 (3.4) 
513 (6.2) 
 
1.00 
1.88 (1.04-3.19) 
- 
CD4 T cell count (cells/μl): 
≥ 500 
200-499 
<200 
 
387 (4.4) 
543 (5.5) 
110 (2.7) 
 
1.00 
1.27 (0.69-2.34) 
0.61 (0.18-2.12) 
- 
WHO HIV clinical stage 
I or II 
III or IV 
 
905 (5.0) 
131 (3.8) 
 
1.00 
0.76 (0.30-1.95) 
- 
Season of enrolment 
Dry 
Rainy 
 
579 (2.6) 
459 (7.4) 
 
1.00 
3.01 (1.62-5.59) 
 
1.0 
3.04 (1.63-5.67) 
MUAC* 
≥ 22.5 cm 
<22.5 cm 
 
929 (5.3) 
87 (1.2) 
 
1.0 
0.21 (0.03-1.53) 
- 
Body Mass Index kg/m
2
 (%) 
>24.9 
18.5-24.9 
< 18.5 
 
260 (3.9) 
760 (5.1) 
16 (6.3) 
 
1.00 
1.35 (0.67-2.75) 
1.67 (0.20-13.80) 
- 
Socio-economic status (%) 
High 
Middle 
Poor 
 
236 (3.8) 
382 (4.2) 
408 (5.4) 
 
1.00 
1.10 (0.48-2.54) 
1.44 (0.65-3.18) 
- 
 
*MUAC= mid-upper arm circumference 
** Adjusted for gravidity, cotrimoxazole intake and season of enrolment 
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Table 5.2: Characterization of HIV-infected pregnant women by malaria infection attending Thyolo district Hospital antenatal clinic, 
Malawi (2005-2009) 
 Characteristic Type of malaria infection p-value 
Microscopic 
n=61 
Submicroscopic 
n=50 
None 
n=990 
Across strata None vs. 
Submic** 
None vs. 
Micro** 
Micro vs. 
Submic** 
Age in years , median (range) 26 (18-35) 25 (18-46) 27 (16-45) 0.02 0.26 0.0007 0.55 
Gravidity  
Primigravidae (%) 
Secundigravidae (%) 
 
8 (6.6) 
17 (27.9) 
 
7 (14.2) 
10 (20.4) 
 
58 (5.9) 
112 (16.6) 
 
0.02 
 
0.04 
 
0.07 
 
0.33 
 
Bed net use*  
Yes (%) 
 
20 (34.5) 
 
29 (59.2) 
 
604 (61.3) 
 
0.0003 
 
0.77 
 
<0.0001 
 
0.01 
Enrolment Season 
Rainy (%) 
 
37 (60.7) 
 
34 (69.4) 
 
425 (43.0) 
 
<0.0001 
 
0.0003 
 
0.007 
 
0.34 
SP-IPT use (%) 
Yes  
 
42 (71.2) 
 
36 (73.5) 
 
618 (63.6) 
 
0.20 
 
0.16 
 
0.24 
 
0.79 
Cotrimoxazole prophylaxis 
Yes 
 
10 (16.4) 
 
15 (30.0) 
 
472 (47.7) 
 
0.0001 
 
0.01 
 
<0.0001 
 
0.09 
CD4  cell count (cells/μl) 
<200 (%) 
200-499 (%) 
≥ 500 (%) 
 
6 (9.8) 
31 (50.8) 
24 (39.4) 
 
3 (6.0) 
30 (60.0) 
17 (34.0) 
 
107 (10.8) 
513 (51.8) 
370 (37.4) 
 
0.75 
 
0.49 
 
 
 
0.94 
 
0.56 
WHO HIV clinical stage (%) 
I or II 
III or IV 
 
58 (96.7) 
2 (3.3) 
 
45 (90.0) 
5 (10.0) 
 
860 (87.2) 
126 (12.8) 
 
0.07 
 
0.56 
 
0.03 
 
0.24 
Antiretroviral drug use (%) 
Yes 
 
11 (18.0) 
 
18 (36.0) 
 
509 (51.4) 
 
0.0001 
 
0.03 
 
<0.0001 
 
0.03 
 
Body Mass Index : Median(range) 22.6 (18.5-30.9) 
 
22.7 (17.2-29.4) 23.3 (11.7-36.7) 0.04 0.15 0.03 0.61 
 
MUAC :Median (range) 24.2 (20.5-30.8) 24.9 (22.4-27.8) 
 
25.0 (18.0-36.8) 0.01 0.99 0.004 0.03 
Socio-economic status (%) 
Poor 
Middle 
High 
 
30 (49.2) 
25 (41.0) 
6 (9.8) 
 
22 (46.8) 
16 (34.0) 
9 (19.2) 
 
386 (39.4) 
366 (37.4) 
227 (23.2) 
 
0.13 
 
0.59 
 
0.05 
 
0.36 
*Bed net use  missing in groups: Microscopic : n=3; Submicroscopic: n=1; No malaria :n=5 
**Submic=Submicroscopic malaria infection ; Micro=Microscopic malaria infection 
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Table 5.3: Factors associated with maternal anemia in HIV-infected pregnant women attending Thyolo district Hospital antenatal clinic in Malawi 
(2005-2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic n(% anemic) Crude PR (95% CI) Adjusted PR (95%CI)¥ 
Type of malaria infection 
None 
Submicroscopic 
Microscopic 
 
989 (42.7) 
50 (68.0) 
61 (62.3) 
 
1.00 
1.59 (1.30-1.95) 
1.46 (1.19-1.80) 
 
1.00 
1.44 (1.17-1.78) 
1.34 (1.10-1.63) 
Age in years  
≥ 27 
<27 
 
599 (43.7) 
540 (46.5) 
 
1.00 
1.06 (0.93-1.21) 
 
1.00 
0.98 (0.85-1.13) 
Gravidity (%) 
Multigravidae 
Secundigravidae 
Primgravidae 
 
867 (43.7) 
102 (50.8) 
71 (45.1) 
 
1.00 
1.16 (0.99-1.36) 
1.03 (0.79-1.35) 
 
1.00 
1.11 (0.95-1.29) 
1.03 (0.79-1.34) 
Bed net use 
Yes 
No 
 
673 (44.6) 
458 (45.4) 
 
1.00 
1.02 (0.89-1.16) 
 
1.00 
1.06 (0.93-1.20) 
Iron supplementation 
Yes 
No 
 
1063 (44.1) 
68 (58.8) 
 
1.00  
1.33 (1.08-1.64) 
- 
SP-IPTp 
Yes 
No 
 
728 (48.2) 
391 (39.4) 
 
1.00 
1.22 (1.06-1.41) 
- 
Cotrimoxazole use 
Yes 
No 
 
510 (35.3) 
630 (53.0) 
 
0.67 (0.58-0.76) 
1.00 
 
0.69 (0.59-0.80) 
Intestinal parasitic infection 
Yes 
No 
 
126 (45.2) 
960 (44.9) 
 
1.01 (0.82-1.24) 
1.00 
- 
CD4 T cell count (cells/μl): 
≥ 500 
200-499 
<200 
 
424 (36.1) 
597 (48.1) 
119 (62.2) 
 
1.00 
1.33 (1.14-1.55) 
1.72 (1.43-2.08) 
 
1.00 
1.33 (1.14-1.56) 
1.69 (1.39-2.06) 
¥ Adjusted for age, gravidity, bed net use, cotrimoxazole prophlaxis, CD4 count, season of enrolment, BMI and socio-economic status 
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Continued Table 5.3  
 
 
 
 
 
 
 
 
 
 
 
Table 5.4: Hemoglobin concentration (Hb) by malaria infection in HIV-infected pregnant women at Thyolo district Hospital, Malawi 
(2005-2009) 
 
 
 
 
 
Characteristic n(% anemic) Crude PR (95% CI) Adjusted PR (95%CI)¥ 
WHO HIV clinical stage 
III or IV 
I or II 
 
139 (34.5) 
996 (46.3) 
 
1.00 
0.75 (0.59-0.95) 
- 
Antiretroviral drug use (%) 
Yes 
No 
 
554 (37.2) 
586 (52.6) 
 
1.00 
1.41 (1.24-1.61) 
- 
Season of enrolment 
Dry 
Rainy 
 
617 (43.8) 
521 (46.5) 
 
1.00 
1.06 (0.93-1.21) 
 
1.00 
0.98 (0.86-1.11) 
BMI (%) 
>24.9 
18.5-24.9 
< 18.5 
 
281 (40.2) 
839 (46.0) 
16 (68.8) 
 
1.00 
1.14 (0.97-1.34) 
1.71 (1.19-2.45) 
 
1.00 
1.07 (0.91-1.26) 
1.50 (1.01-2.25) 
Socio-economic status (%) 
High 
Middle 
Poor 
 
252 (44.1) 
421 (46.1) 
452 (44.3) 
 
1.00 
1.05 (0.88-1.24) 
1.00 (0.84-1.19) 
 
1.00 
1.05 (0.89-1.24) 
1.03 (0.87-1.21) 
¥ Adjusted for age, gravidity, bed net use, cotrimoxazole prophlaxis, CD4 count, season of enrolment, BMI and socio-economic status  
Malaria infection n Mean Hb  (SD)* Difference in Hb means (95% CI)§ p-value 
 
No malaria 
Submicroscopic 
Microscopic 
 
990 
50 
61 
 
11.17 (1.35) 
10.38 (1.34)a 
10.35 (1.27)b 
 
Ref 
-0.74 (-1.13,-0.35) 
-0.61 (-0.98,-0.25) 
 
Ref 
0.0002 
0.001 
*Analysis of variance test for the means: <0.0001 
§ Adjusted for CD4 cell count and cotrimoxazole intake. 
a= Student’s t-test between Submicroscopic infection and no malaria groups; p<0.0001 
b= Student’s t-test between Microscopic infection and No malaria groups; p<0.0001 
  
 
CHAPTER 6: ASSOCIATION OF IRON SUPPLEMENTATION AND IRON DEFICIENCY 
WITH MALARIA INFECTION IN HIV-INFECTED PREGNANT WOMEN IN MALAWI 
 
ABSTRACT 
Background: Evidence suggests that iron supplementation in individuals living in malaria-
endemic areas could increase the risk of malaria. The effect of iron supplementation or iron 
deficiency on malaria infection in HIV-infected pregnant women is unknown.  
Methods: HIV-infected pregnant women attending Thyolo district hospital antenatal clinic for 
routine services were recruited from December 2005 to July 2009 (N=1,142). Peripheral 
blood was tested for hemoglobin concentration (Hb) and malaria infection using light 
microscopy and RT-PCR. Serum ferritin, transferrin receptors, serum iron were measured in 
455 women. Information on socio-demographics, obstetric and medical history, use of 
malaria control interventions during pregnancy was collected using a standardized 
questionnaire and antenatal records.  
Findings: Of the 1,133 women with information on iron supplementation, 94.0% reported 
taking iron supplements during pregnancy. The prevalence of microscopic and PCR-
detected malaria infection was similar between women who took iron supplements and 
those who did not (Adjusted Odds Ratio (AOR), [95%CI): 2.50, [0.89-7.06 and 1.42, [0.61-
3.33] respectively) adjusted for age, gravidity, bed net use, socio-economic status, antenatal 
visits, SP-IPTp and cotrimoxazole intake. Women with iron deficiency were less likely to 
have microscopic infection or PCR-detected malaria infection (AOR, [95%CI]: 0.22, [0.11-
0.47] and 0.21, [0.12-0.39] respectively) adjusted for intestinal parasitic infections. 
Conclusion: Findings suggest iron supplementation did not appear to increase the risk of 
malaria and iron deficiency was associated with reduced malaria infection in HIV-infected 
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pregnant women. However, data from longitudinal research are still needed to determine the 
effect of iron supplementation on malaria in iron replete pregnant women living in malaria 
endemic areas. 
Introduction 
Iron deficiency (ID) is the most common nutritional deficiency affecting over 2 billion 
people worldwide and is the primary cause of anemia  [106, 108]. Pregnant women and 
children are particularly susceptible due to high iron demands of growth and pregnancy. 
Anemia among pregnant women is high in sub-Saharan countries ranging between 57% 
and 86% [108, 109]. Anemia in pregnancy increases the risk of preterm labor, fetal 
abnormalities and low birth weight [116-118, 123, 270-275] which are significant causes of 
perinatal morbidity and mortality.  
The World Health organization (WHO) recommends routine iron supplementation 
during pregnancy to prevent anemia and its adverse effects [106, 107]. However, evidence 
suggests that iron supplementation in individuals living in malaria-endemic areas may 
increase the risk of malaria infection [221-223]. Increased replication of malaria parasites 
has been observed in iron replete mice compared to iron deficient mice [82, 224]. Few 
studies on the effects of iron on malaria infection in pregnant women have been published 
[91-94]. Studies in pregnant women of unknown HIV status have shown that women with 
iron deficiency (ID) are less likely to have malaria compared to iron replete women [95, 96]. 
Conflicting findings have been reported from studies on the effect of iron supplementation 
on malaria in pregnant women [91-94]. The observed differences in the study findings can 
be attributed to variation in the study participants, routes of iron administration, level of 
malaria transmission in the study areas and study methods and design. Studies from 
Thailand and Papua New Guinea found that use of iron supplementation increased the risk 
of malaria [92, 93]. However, differences between the treatment and the comparison groups 
could have confounded the results. Iron was provided only to women who had anemia and 
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the comparison group was composed of women without anemia. A randomized placebo-
controlled trial in rural Gambia found that iron supplementation did not increase the risk of 
malaria [91]. However, this study only recruited multigravid women who may have lower risk 
of malaria compared to primigravid women [6, 12]. Also, women in the treatment group in 
Papua New Guinea were given intravenous iron while those in the Gambian study received 
oral iron [91, 93]. It is still not clear from these studies whether iron supplementation 
increases the risk of malaria in pregnant women and no study has assessed the effect of 
iron supplementation or iron deficiency on malaria in HIV-infected pregnant women. 
Iron supplementation could be more harmful in HIV-infected pregnant women 
compared to HIV-uninfected pregnant women. First, HIV-infected pregnant women have 
lower malaria immunity compared to HIV-uninfected pregnant women [51, 52, 220]. Second, 
studies have found that iron accumulates in body tissues and abnormal iron metabolism due 
to chronic HIV infection does occur in HIV-infected individuals [225-227]. In HIV-infected 
persons, high iron levels are associated with increased microbial infections and mortality 
[151, 153, 182, 195]. 
We analyzed data from a cross-sectional study that recruited HIV-infected pregnant 
women attending the antenatal clinic for routine services at Thyolo district hospital in 
Malawi. We assessed whether iron supplementation increased malaria infection in HIV-
infected pregnant women. We also examined whether iron deficiency is associated with 
reduced malaria infection. 
Methods 
Study site 
This study was conducted at Thyolo hospital, a public health facility located in a rural 
district in southern Malawi between December 2005 and July 2009. Antenatal and HIV 
services are offered free of charge. All HIV-positive patients including HIV-infected pregnant 
women assessed as being in WHO HIV clinical stage III or IV, or with a CD4 count <250 
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cells/mm3 irrespective of clinical staging were eligible for antiretroviral therapy (ART). The 
first-line ART regimen was a fixed-dose combination of stavudine (d4T), lamivudine (3TC) 
and nevirapine (NVP) (Triomune) [244]. The ANC has a well-established HIV Voluntary 
Counseling and Testing service (VCT) and a nevirapine treatment program to prevent 
mother-to-child transmission (MTCT) of HIV.  
Study participants and recruitment 
HIV-infected pregnant women with ≥34 weeks gestation attending routine services at 
Thyolo district Hospital antenatal clinic were enrolled. Women were excluded if <15 years 
and with immediate life-threatening medical and obstetric conditions. Socio-demographic 
and medical information were obtained using a standardized questionnaire and antenatal 
records. Physical medical examination included measurement of MUAC, weight and height. 
The study was approved by the Malawi College of Medicine Research and Ethics 
Committee and by institutional review board of the University of North Carolina at Chapel 
Hill. 
Laboratory procedures 
Serum ferritin and serum iron were measured using ELISA kits (Roche Diagnostics, 
Switzerland). sTFR concentrations were measured using an enzyme immunoassay (Ramco 
Laboratories, Texas, USA). C-reactive protein (CRP) concentrations were measured by 
ELISA (Immuno-Biological Laboratories [IBL], Hamburg, Germany). Hemoglobin 
concentration (Hb) was measured using a Hemocue hemoglobinometer (HemoCue AB, 
Ängelholm, Sweden). Malaria infection was detected using two methods as described in 
section 3.1.3 above. Briefly, light microscopy was used to examine thick blood smears for 
asexual forms of malaria parasites. Malaria parasite DNA was extracted from dried blood 
spots on filter papers using an invitrogen PureLink Genomic DNA kit (Invitrogen, Carlsbad, 
USA) as per manufacturer’s instructions. PCR amplification of the malaria parasite DNA was 
done in two steps using a pooling method as described in [231]. Stool samples were 
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examined for helminth infection. First, macroscopic examination for the presence of pus, 
mucus, blood or worms was done. Samples were then prepared for microscopic 
examination using saline wet mount for detection of hookworm ova and cysts detection, 
followed by iodine wet mount for identification of cysts. CD4 count was performed using the 
FACS count flow [70]cytometer (Becton-Dickinson, San Jose, CA). 
Definitions 
Microscopic malaria infection was defined as presence of malaria parasites on 
microscopy and result was positive and PCR-detected malaria infection was defined as 
positive malaria result irrespective of microscopy results. 
Iron deficiency was defined as ferritin concentration <30 μg/L for women with CRP of 
8.2 mg/L (i.e. iron deficiency in the absence of inflammation) or ferritin <70 μg/L for women 
with CRP of > 8.2 mg/L (i.e. iron deficiency in presence of inflammation) [96]. 
Statistical analyses 
Data were analyzed using SAS software version 9.1 (SAS Institute Inc., Cary, NC, 
USA). In bivariate analyses, Pearson chi-square test, analysis of variance (ANOVA) or 
student’s t-test and Kruskal-Wallis test or Wilcoxon rank sum test were used to compare 
between outcomes or exposure and categorical variables, normally distributed variables and 
non-normally distributed variables respectively.   
Directed acyclic graph (DAGs) was used to identify potential confounders for the 
association between iron supplementation or iron deficiency and malaria infection [239-241]. 
A backward elimination strategy was applied to select the best model using the absolute 
change in estimate criterion of at least 10%.  Variables that were assessed for confounding 
the association between iron supplementation and malaria infection included; age (<27years 
or ≥27years), gravidity (primigravidae, secondigravidae and Multigravidae), CD4 cell count 
(< 200, 200–499 and ≥ 500 cells/µL), body mass index (BMI), intestinal infection, and socio-
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economic status (SES-(poor, middle and high)). SES was obtained by calculating the wealth 
index using the method as described in [[246, 247, 267]]. Education, employment status, 
housing building materials, household sanitation and water sources were used in calculating 
the household wealth index in our study.  Effect measure modification (EMM) was evaluated 
using likelihood ratio test of the interaction term. Logistic regression model was used to 
assess the association between iron supplementation or iron deficiency and malaria 
infection. 
Study population  
Data on iron supplementation was available in 99.2% (1,133/1,142) of the women 
enrolled. The mean age was 27.2 years (SD; 5.2), 6.3% (71/1,133) were primigravidae and 
a median (range) of CD4 count of 423 cells/µL (11-1528 cells/µL). Use of bed nets was 
reported in 59.6% (675/1133) of the women and 45.1% (497/1,101) and 48.9% (538/1,101) 
of the women reported using bed nets, taking CTX and ARVs during pregnancy 
respectively. The mean (standard deviation) of BMI and MUAC were 453.6 cells/µL (224.9), 
23.4 kg/m2 (2.5) and 24.9 cm (2.0) respectively 
Iron supplementation  
Among women with information on iron supplementation, 94.0% (1,065/1,133) 
reported taking iron supplements during pregnancy. The distributions of age, gravidity, CD4 
cell count, WHO HIV disease clinical stage, MUAC, BMI, socio-economic status and 
intestinal helminthes infections were not different across the iron supplementation groups 
(Table 6.1). Women who reported taking iron supplements were more likely to make more 
visits, use bed nets and report taking SP-IPTp, ARVs or CTX compared to women who did 
not (Table 6.1).  
The prevalence of anemia was lower in women who reported taking iron compared 
to those who did not (44.1% versus 58.8%; p=0.02). Compared to women who took iron for 
<30 days, the prevalence of anemia was not different in women who reported taking iron for 
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31-60 days (47.3% versus 44.0%; p=0.34) and was lower in women who took iron for >60 
days (47.3% versus 38.4%; p=0.03). However, the hemoglobin concentrations were similar 
between women who took iron supplements and those who did not (Median =11.1g/dl; 
range 6.2-15.5 versus 10.8g/dl; range 6.2-13.7 respectively).  
Association between iron supplementation and malaria infection 
The odds of microscopic and PCR-detected malaria infection were higher in women 
who reported not taking iron supplements than women who did (Odds Ratio (OR), [95%CI] 
3.47, [1.67-7.19) and 2.30, [1.21-4.36] respectively) (Table 6.4). 
After adjusting for age, gravidity, bed net use, socio-economic status, antenatal 
visits, SP-IPTp and CTX intake, the odds of microscopic and PCR-detected malaria infection 
were similar between women who took iron supplements and those who did not (Adjusted 
Odds Ratio (AOR), [95%CI): 2.50, [0.89-7.06 and 1.42, [0.61-3.33] respectively) (Table 6.4). 
The odds of microscopic or PCR-detected malaria infection were not different across the 
levels of duration or the frequency of iron supplementation (Table 6.4). The parasite density 
was not different between women who took iron supplements compared to those who did 
not (Median 2000 parasites/μL blood; IQR 520-4160 parasites/μL blood versus 1420 
parasites/μL blood; IQR 440-7640 parasites/μL blood) among the participants who had 
microscopic malaria infection. 
Iron status biomarkers 
Iron status biomarkers were measured in the first 39.8% (455/1,142) women 
recruited in the study. The median serum ferritin level was higher in women who reported 
taking iron supplementation compared to those who did not (Median 18.0μg/L; IQR 11.0-
31.0 versus 13.0μg/L; IQR 9.0-20.5; p=0.005) (Table 6.2). Median levels of serum iron and 
sTfR were not different between the iron supplementation groups as well as across the 
levels of iron supplementation duration. The prevalence of iron deficiency was 84.4% 
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(384/455) and was lower in women who took iron compared to those who did not (83.4% 
versus 96.9%; p=0.04).  
Age less than 27 years (Adjusted prevalence ratio (APR) 1.11; 95%CI 1.02-1.20) and not 
taking iron supplementation (APR 1.15; 95%CI 1.07-1.25) were associated with increased 
prevalence of iron deficiency, adjusted for HIV clinical stage, MUAC and ARV use (Table 
6.3). Gravidity, CD4 count, ARV use, SES, BMI, MUAC and intestinal helminth infections 
were not associated with iron deficiency.     
Association between iron deficiency and malaria infection 
Women with iron deficiency were less likely to have microscopic infection or PCR-
detected malaria infection (AOR, [95%CI]: 0.22, [0.11-0.47] and 0.21, [0.12-0.39] 
respectively) adjusted for intestinal parasitic infections (Table 6.4). The parasite density was 
not different between women who had iron deficiency compared to those with adequate iron 
stores (Median 2000 parasites/μL blood; IQR 680-5520 parasites/μL blood versus 2120 
parasites/μL blood; IQR 1240-3680 parasites/μL blood) among the participants who had 
microscopic malaria infection. 
Discussion 
This study assessed the association between iron supplementation and malaria 
infection and investigated whether iron deficiency is protective against malaria infection in 
HIV-infected pregnant women. Microscopic and PCR-detected malaria infection was similar 
between women who reported taking iron supplements and those who did not. There was 
no association between duration or frequency of iron supplementation and microscopic or 
PCR-detected malaria infection. Women with iron deficiency were less likely to have 
microscopic or PCR-detected malaria infection compared to iron replete women.  
Previous studies on iron supplementation and malaria in pregnant women of unknown 
HIV status have reported conflicting results. While some studies have found that iron 
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supplementation increases the risk of malaria [92, 93], others found no association [91]. 
After adjusting for confounders we found that malaria infection was similar between the 
women who took iron supplements during pregnancy and those who did not. Before 
adjustment, malaria infection was higher in women who reported not taking iron 
supplements. Poor use of health services and malaria prevention interventions may partly 
explain the high prevalence of malaria in women who reported not taking iron supplements. 
These women were less likely to use bed nets, or take SP-IPTp or CTX and made less 
antenatal visits.       
Studies have shown that pregnant women with iron deficiency are less likely to have 
malaria compared to pregnant women with adequate iron stores [95, 96] which is consistent 
with our findings. Iron deficient women were less likely to have microscopic or PCR-detected 
malaria infection. However, the parasite density was not different in the two groups, 
probably due to low statistical power as a result of the small number of women who had 
microscopic malaria in our study. Iron is required by malaria parasites for DNA replication 
[81]. The specific sources of iron in the body and mechanisms through which iron affects 
malaria parasite are not fully understood [reviewed in [83, 84]]. It is suggested that serum 
iron, free erythrocytic iron and hemoglobin are the possible sources [84]. Four theories 
explain how iron status may influence susceptibility to malaria [reviewed in [85]]. First, it is 
thought that during the red blood cell stage of malaria infection, the parasite is dependent on 
the small pool of labile iron in the cell cytoplasm [83, 86]. The concentration of labile iron in 
the cytoplasm is thought to be sensitive to nutritional influences including iron 
supplementation [83, 87]. This is confirmed by a study in mice which showed that inhibition 
of malaria parasite growth was achieved in red blood cells independent of the of iron status 
level [88]. Second, iron supplementation enhances malaria susceptibility by stimulating 
formation of young red blood cells. This may increase the risk of infection with P.vivax and 
P. ovale species that have preference for young red blood cells [89]. Third, in the iron 
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deficiency state, zinc protoporphyrin is produced and is thought to inhibit detoxification of 
heme, and this generates a toxic environment which acts as an antimalarial drug [90]. 
Fourth, it is thought that “nutritional immunity”, an iron withholding defense system, 
withholds the growth essential iron from the invading pathogens including malaria parasites 
[reviewed in [127, 130]].   
Our study had limitations. First, the cross-sectional design allowed only one point 
measurement of both the outcome and malaria infection in the third trimester; hence, no 
causal inferences can be made. Second, information on the use of iron supplementation 
during pregnancy was self-reported. Although this information was verified with antenatal 
records to ensure a prescription was made, this does not reflect compliance with intake of 
the supplements. Therefore, it is possible that our results may have been affected by 
misclassification of iron supplementation, duration or frequency of intake. Third, it may be 
argued that there is a potential for iron deficiency misclassification in our study. Currently, 
there are no standard cut-off points for iron biochemical markers to indicate iron deficiency 
in HIV-infected individuals. Our study used the cut-off points that were used in previous 
similar studies [95, 96]. Iron deficiency was defined as ferritin concentration <30 μg/L for 
women with CRP of 8.2 mg/L (i.e. iron deficiency in the absence of inflammation) or ferritin 
<70 μg/L for women with CRP of > 8.2 mg/L (i.e. iron deficiency in presence of 
inflammation). However, their CRP cut-off point of 8.2 ng/mL is lower than 10 mg/L which 
has been suggested by others [276].  However, we found no significant differences when we 
analyzed our data using the CRP cut-off point of 10mg/L. Other investigators have 
suggested that sTFR-Ferritin index is a better indicator of iron deficiency especially in areas 
with high rates of infection [214, 215]. We found no significant difference when we used the 
sTfR-Ferritin index cut-off point of >2.0 to indicate iron deficiency [215].  We were unable to 
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analyze our data using sTfR-Ferritin index cut-off point of >5.3 as suggested by Phiri et al. 
due to a small number of women who were iron deficient using this classification.     
In conclusion, iron supplementation did not increase the prevalence of malaria 
infection and iron deficiency was associated with reduced malaria infection in HIV-infected 
pregnant women. Our findings suggest that iron supplementation should not be withheld 
from HIV-infected pregnant women living in malaria-endemic areas but they should be 
encouraged to utilize malaria prevention to avoid infections and associated 
complications.[79] However, data from longitudinal research are still needed to determine 
the effect of iron supplementation on malaria in iron replete pregnant women living in 
malaria-endemic areas.  
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Table 6.1: Characteristics of HIV-infected pregnant women by iron supplementation 
attending Thyolo district Hospital antenatal clinic, Malawi (2005-2009) 
 
Characteristic Total  
(n=1,133) 
Iron  
(n=1,065) 
No iron  
(n=68) 
p-value 
Age in years  
≥ 27 
<27 
 
595 (52.5) 
538 (47.5) 
 
556 (52.2) 
509 (47.8) 
 
39 (57.4) 
29 (42.6) 
 
0.41 
Gravidity (%) 
Primigravidae  
Secundigravidae 
 
71 (6.3) 
201 (17.7) 
 
67 (6.3) 
184 (17.3) 
 
4 (5.9) 
17 (25.0) 
 
0.27 
Bed-net use (%) * 
Yes 
 
670 (59.6) 
 
642 (60.7) 
 
28 (41.2) 
 
0.001 
Antenatal visits * 
Median: range 
≥ 3 visits (%) 
 
3 (1-8) 
681 (60.2) 
 
3 (1-8) 
676 (63.5) 
 
1 (1-4) 
5 (7.4) 
 
 
<0.0001 
SP-IPTp (%) * 
Yes 
 
727 (65.3) 
 
705 (66.5) 22 (41.5) 
 
0.0002 
Cotrimoxazole use (%) 
Yes 
 
506 (44.7) 
 
498 (46.8) 
 
8 (11.8) 
 
<0.0001 
Antiretroviral drug use (%) 
Yes 
 
551 (48.6) 
 
554 (51.1) 7 (10.3) 
 
<0.0001 
CD4 T cell count (cells/μl): 
<200 
200-499 
≥ 500 
 
119 (10.4) 
592 (52.3) 
422 (37.3) 
 
11 (10.4) 
558 (52.4) 
396 (37.2) 
 
8 (11.8) 
34 (50.0) 
26 (38.2) 
 
0.91 
WHO HIV clinical stage* 
I or II 
III or IV 
 
990 (87.8) 
138 (12.2) 
 
927 (87.5) 
133 (12.5) 
 
63 (92.7) 
5 (7.4) 
 
0.21 
MUAC 
≥ 22.5 cm 
<22.5 cm 
 
1003 (90.4) 
106 (9.4) 
 
944 (90.6) 
98 (9.4) 
 
59 (88.1) 
8 (11.9) 
 
0.49 
Body Mass Index*: kg/m
2
 (%) 
>24.9 
18.5-24.9 
< 18.5 
 
280 (24.8) 
836 (74.0) 
13 (1.2) 
 
267 (25.1) 
783 (73.7) 
12 (1.1) 
 
13 (19.4) 
53 (79.1) 
1 (1.5) 
 
0.56 
Socio-economic status* (%) 
Poor 
Middle 
High 
 
449 (40.1) 
417 (37.3) 
253 (22.6) 
 
425 (40.4) 
387 (36.7) 
241 (22.9) 
 
24 (36.4) 
30 (45.4) 
12 (18.2) 
 
0.35 
 
Hemoglobin g/dl:  
Median (IQR) 11.0 (10.1-11.9 ) 11.1 ( 10.2-11.9) 10.8 ( 9.8-11.7) 0.16 
Anemia: < 11g/dl 
Yes 
 
509 (45.0) 
 
469 (44.1) 
 
40 (58.8) 
 
0.02 
*Factors with total n not equal to 1,133 due to missing values. 
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Table 6.2: Iron supplementation and iron status biomarkers in HIV-infected pregnant women at Thyolo district Hospital, Malawi 
(2005-2009) 
 Iron biomarker Total 
(n=455) 
Iron supplementation Duration of iron supplementation 
Yes 
(n=421) 
No 
(n=32) 
p-value < 30 days 
(n=186) 
31-60 days 
(n=158) 
>60 days 
(n=69) 
p-value 
Ferritin (μg/L):Median (IQR)* 18.0 (11.0-31.0) 18.0 (11.0-33.0) 13 (9.0-20.5) 0.005 16.0 (11.0-32.0) 17.0 (11.0-28.0) 24 (16.0-45.0) 0.01 
sTFR (mg/L): Median (IQR) 1.8 (1.4-2.3) 1.8 (1.5-2.3) 1.6 (1.4-2.0) 0.19 1.8 (1.5-2.3) 1.7 (1.5-2.3) 1.8 (1.4-2.4) 0.59 
Serum iron (μmol/L): Median 
(IQR) 
13.0 (9.0-18.0) 13.5 (10.0-19.0) 12.0 (7.0-16.0) 0.18 13.0 (9.0-17.5) 14.0 (9.0-19.0) 15.0 (11.0-22.0) 0.05 
Iron deficiency 
Yes (%) 
 
84.4 
 
83.4 
 
96.9 
 
0.04 
 
84.4 
 
85.4 
 
76.8 
 
0.25 
sTFR-F index 
>2.0 
 
25.5 
 
25.2 
 
31.3 
 
0.45 
 
28.0 
 
24.7 
 
18.8 
 
0.34 
*IQR=Interquartile range  
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Table 6.3: Factors associated with iron deficiency in 455 HIV-infected pregnant women 
attending Thyolo district Hospital antenatal clinic in Malawi (2005-2009) 
 
 
 
 
 
 
Characteristic n(% iron deficient) Crude PR (95% CI) Adjusted PR 
(95%CI)¥ 
Age in years  
≥ 27 
<27 
 
216 (79.6) 
239 (88.7) 
 
1.00 
1.11 (1.03-1.21) 
 
1.00 
1.11 (1.02-1.20) 
Gravidity (%) 
Multigravidae 
Secundigravidae 
Primgravidae 
 
324 (83.0) 
92 (88.0) 
39 (84.6) 
 
1.00 
1.06 (0.97-1.16) 
1.02 (0.88-1.17) 
- 
Iron supplementation 
Yes 
No 
 
421 (83.4) 
32 (96.9) 
 
1.00  
1.16 (1.08-1.25) 1.15 (1.07-1.25) 
Intestinal parasitic infection 
No 
Yes 
 
359 (83.3) 
73 (87.7) 
 
1.00 
1.05 (0.95-1.15)  
CD4 T cell count (cells/μl): 
≥ 500 
200-499 
<200 
 
134 (36.1) 
256 (48.1) 
65 (62.2) 
 
1.00 
0.99 (0.91-1.08) 
0.98 (0.86-1.11)  
WHO HIV clinical stage 
I or II 
III or IV 
 
386 (85.5) 
69 (78.3) 
 
1.00 
0.91 (0.80-1.04) 0.95 (0.81-1.13) 
Antiretroviral drug use (%) 
Yes 
No 
 
83 (79.5) 
372 (85.4) 
 
1.00 
1.08 (0.96-1.21) 1.01 (0.87-1.17) 
Season of enrolment 
Dry 
Rainy 
 
201 (86.1) 
254 (83.1) 
 
1.00 
0.97 (0.89-1.04) 
 
- 
BMI (%) 
>24.9 
18.5-24.9 
< 18.5 
 
281 (89.6) 
839 (83.0) 
5 (80.0) 
 
1.08 (0.99-1.17) 
1.00 
0.96 (0.62-1.50) 
- 
MUAC 
≥ 22.5 cm 
<22.5 cm 
 
401 (85.3) 
52 (76.9) 
 
1.00 
0.90 (0.77-1.05) 
 
 
1.11 (0.94-1.30) 
Socio-economic status (%) 
High 
Middle 
Poor 
 
91 (85.7) 
167 (86.2) 
195 (85.6) 
 
1.00 
1.00 (0.91-1.12) 
0.96 (0.87-1.07) 
 
- 
¥ Adjusted for  age, HIV clinical stage, antiretroviral drug use, mid-upper arm circumference and iron 
supplementation 
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Table 6.4: Association of iron supplementation and iron deficiency with malaria infection in HIV-infected pregnant women attending 
Thyolo district Hospital antenatal clinic, Malawi (2005-2009) 
 
Characteristic Microscopic malaria infection PCR-detected malaria infection 
n (% infected) Crude OR (95% CI) Adjusted OR (95% CI) n (% infected) Crude OR (95% CI) Adjusted OR (95% CI) 
Iron supplementation  
Yes 
No 
 
1038 (4.8) 
67 (14.9) 
 
1.00 
3.47 (1.67-7.19) 
 
1.00 
2.50 (0.89-7.06)
a 
 
1051 (9.3) 
68 (19.1) 
 
1.00 
2.30 (1.21-4.36)
 
 
1.00 
1.42 (0.61-3.33)
 a
 
Duration of iron 
supplementation 
>60 days 
31-60 days 
≤30 days 
 
230 (3.0) 
402 (6.2) 
403 (4.2) 
 
1.00 
2.11 (0.90-4.96) 
1.40 (0.57-3.44) 
 
1.00 
1.19 (0.34-3.83)
b 
1.60 (0.64-4.02) 
 
235 (6.8) 
401 (9.5) 
408 (9.8) 
 
1.00 
1.43 (0.78-2.63)
 
1.49 (0.81-2.72) 
 
1.00 
1.15 (0.60-2.19)
d 
0.81 (0.35-1.84) 
Frequency of iron 
supplementation 
Always 
Most times 
Sometimes/Rarely 
 
250 (4.0) 
711 (5.1) 
73 (6.9) 
 
1.00 
1.28 (0.63-2.62) 
1.77 (0.58-5.34) 
 
 
1.00 
0.81 (0.37-1.75)
c
 
0.57 (0.14-2.37) 
 
253 (8.3) 
715 (9.1) 
78 (14.1) 
 
1.00 
1.11 (0.66-1.85)
 
1.81 (0.83-3.95) 
 
1.00 
0.94 (0.54-1.65)
e 
1.19 (0.48-2.98) 
Iron deficiency * 
No 
Yes 
 
63 (22.2) 
370 (7.8) 
 
1.00 
0.30 (0.15-0.60) 
 
1.00 
0.22 (0.11-0.47)
f 
 
71 (35.2) 
384 (12.0) 
 
1.00 
0.25 (0.14-0.45) 
 
1.00 
0.21 (0.12-0.39)
 f
 
 
a Adjusted for age, gravidity, bed net use, socio-economic status, antenatal visits, SP-IPTp and cotrimoxazole prophylaxis 
b Adjusted for frequency of iron supplementation, bed net use, cotrimoxazole intake and number of antenatal visits 
c Adjusted for duration of iron supplementation,  bed net use, cotrimoxazole intake and number of antenatal visits 
d Adjusted for  frequency of iron supplementation, cotrimoxazole intake and number of antenatal visits 
e Adjusted for  duration of iron supplementation, cotrimoxazole intake and number of antenatal visits 
f Adjusted for CD4 count, gravidity and intestinal infections 
* Iron deficiency: CRP<8.2mg/L and ferritin <30μg/L or CRP> 8.2mg/L and ferritin <70g/L  
 
  
 
CHAPTER 7: CONCLUSION 
7.1 Summary of findings 
The first aim of this dissertation was to assess the effectiveness of CTX with or 
without SP-IPTp compared to SP-IPTp at reducing malaria infection and maternal anemia in 
HIV-infected pregnant women in Malawi. This study found that CTX with or without SP-IPTp 
was more effective reducing malaria infection and maternal anemia compared to SP-IPTp in 
this study population. 
The second aim was to identify predictors of and assess whether submicroscopic 
malaria infection increases the prevalence of maternal anemia in HIV-infected pregnant 
women. We found that the prevalence of submicroscopic malaria infection was increased in 
primigravid women, during rainy season and in women who did not take CTX prophylaxis. 
Women who had submicroscopic malaria infection had a higher prevalence of maternal 
anemia and lower mean Hb compared to women without malaria infection. 
The third aim was to investigate whether routine iron supplementation increases the 
prevalence of malaria infection in HIV-infected pregnant women in Malawi. We also 
assessed whether iron deficiency was associated with reduced prevalence of malaria 
infection in this population. This study found that routine iron supplementation did not 
increase the prevalence of malaria infection in HIV-infected pregnant women. Women who 
had iron deficiency were less likely to have malaria infection compared to iron replete 
women.  
7.2 Strengths of the study 
Our study was able to provided information on the effectiveness of CTX plus SP-
IPTp versus SP-IPTp to prevent malaria, which is not possible under normal circumstances. 
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The use of CTX plus SP-IPTp to prevent malaria in pregnancy is not recommended 
in HIV-infected pregnant women and it would be deemed unethical to assign women to take 
these drugs in a clinical trial. The policy implementation problems that resulted in some 
women receiving both drugs offered a rare opportunity to answer some of the important 
research questions. 
Our study also used RT-PCR method to detect malaria infection which is more 
sensitive than light microscopy that was used in similar previous studies. We were therefore 
able to detect malaria infection more accurately using this method in our study.  
7.3 Limitations of the study 
The cross-sectional design of our study leads to several limitations. First, it does not 
allow us to make any causal inferences from our findings. Second, our results may be 
biased due to residual confounding by unmeasured factors. Third, we were not able to study 
pertinent public health research questions such as effects of exposures on birth outcomes. 
Fourth, our study was only restricted to the late third trimester and we were unable to 
examine the effects of exposures on the outcomes in the first or second trimester. 
Our exposures such intake of anti-malarial drugs and iron supplementation were self-
reported and verified by checking prescriptions in the antenatal records. However, this does 
not reflect compliance of drug intake. Our results may have been affected by information 
bias. Also there is potential for misclassification of exposures which may have biased our 
estimates towards the null. This is especially possible for iron supplementation where more 
women reported taking iron supplements.   
Because there are no standard cut-off points for iron biomarkers to indicate iron 
deficiency in HIV-infected individuals, there is potential for iron deficiency misclassification. 
Although efforts were made to compare results from different definition of iron deficiency, 
there is still need to devise more accurate ways of detecting iron deficiency especially in 
populations with infections or other causes of inflammation.  
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7.4 Public health implications 
Our findings provide important information which answers important public health 
questions. Our data suggest that CTX is more effective than SP-IPTp in HIV-infected 
pregnant women in Malawi. Hence, efforts should be made to increase CTX availability to all 
HIV-infected pregnant women to reduce the burden of malaria and its complications in this 
population in Malawi. Submicroscopic malaria has clinical significance in HIV-infected 
pregnant women. Efforts should therefore be made to develop cheap and easy to use 
methods to identify these infections in this high risk population. Increased access to malaria 
treatment and malaria control among these women may also reduce the risk of 
submicroscopic malaria infections. Our results also suggest that iron supplementation does 
not increase the risk of malaria in HIV-infected pregnant women in Malawi especially in 
combination with use of malaria prevention interventions.    
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